{"meta":{"query_hash":"3a64bb924a83","filters":{"venue":"Canadian Hematology Today"},"cohort_total":67,"direct_labels_cover":0,"predictions_cover":67,"exported":67,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/3a64bb924a83","api":"https://metacan.xera.ac/api/v1/cohort?venue=Canadian+Hematology+Today"},"results":[{"id":"W4292497528","doi":"10.58931/cht.2022.119","title":"To transplant or not to transplant in multiple myeloma","year":2022,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Multiple myeloma; Melphalan; Transplantation; Autologous stem-cell transplantation; Internal medicine; Oncology; Hematopoietic stem cell transplantation; Stem cell; Surgery; Chemotherapy","score_opus":0.038293469552183476,"score_gpt":0.2977335464162181,"score_spread":0.2594400768640346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292497528","genre_codex":"review","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14450288,0.59208655,0.010407596,0.093298174,0.021432523,0.00044147766,0.00274677,0.0003934778,0.13469042],"genre_scores_gemma":[0.65917104,0.19848447,0.006255173,0.07572927,0.029112916,0.00059914,0.0037189282,0.00025463811,0.02667443],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995956,0.00015524973,0.00004882373,0.000051338495,0.00007147909,0.00007744426],"domain_scores_gemma":[0.99915445,0.00030373386,0.00016365286,0.000037382553,0.00006786235,0.000272911],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009905414,0.00017593872,0.00045200813,0.00034089247,0.00066693936,0.00095509656,0.0003723916,0.001067138,0.016916769],"category_scores_gemma":[0.002839261,0.00006350553,0.00051149505,0.0005147794,0.00035784545,0.0009211141,0.000649351,0.0021340908,0.002901309],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019766341,0.00058407773,0.022608407,0.0028000018,0.0002672931,0.0021871857,0.0004259734,0.0004211171,0.0015127748,0.008118925,0.08885498,0.8702427],"study_design_scores_gemma":[0.0008342958,0.0030841273,0.07275421,0.009736718,0.0010095307,0.029043848,0.000991333,0.0007697663,0.0019875597,0.03282787,0.84681094,0.00014979928],"about_ca_topic_score_codex":0.0003667486,"about_ca_topic_score_gemma":0.0011832849,"teacher_disagreement_score":0.016916769,"about_ca_system_score_codex":0.0005050554,"about_ca_system_score_gemma":0.0006233509,"threshold_uncertainty_score":0.056592286},"labels":[],"label_agreement":null},{"id":"W4384134134","doi":"10.58931/cht.2023.2231","title":"Coronavirus disease (COVID-19) in patients with hematologic malignancy","year":2023,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto","funders":"","keywords":"Coronavirus disease 2019 (COVID-19); Pandemic; Medicine; Coronavirus; Malignancy; Disease; Hematologic malignancy; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); 2019-20 coronavirus outbreak; Outbreak; Virology; Public health; Intensive care medicine; Internal medicine; Infectious disease (medical specialty); Pathology","score_opus":0.12658804367746693,"score_gpt":0.3923899728283335,"score_spread":0.26580192915086653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384134134","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.43583828,0.30685216,0.0008444682,0.07369214,0.001469226,0.00025701802,0.0032203514,0.00008688525,0.17773949],"genre_scores_gemma":[0.88254297,0.104052305,0.00074973295,0.007044507,0.00116066,0.00003909707,0.0010646478,0.000009055742,0.0033369928],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996258,0.00006443613,0.0000278195,0.000028143186,0.00014121078,0.00011261194],"domain_scores_gemma":[0.99962366,0.000052216103,0.000094875875,0.000004955406,0.00008567276,0.00013865155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028234645,0.00013140767,0.00020242625,0.0006639213,0.001031031,0.00057417096,0.00017973865,0.00041274342,0.0030189063],"category_scores_gemma":[0.0015758122,0.00005956976,0.00019978474,0.0011950459,0.00029234952,0.0003058798,0.0006042243,0.00095449435,0.00022155048],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019676788,0.00010042802,0.7870728,0.0007008408,0.00008431158,0.0037172243,0.0013055756,0.00014873045,0.00059295713,0.0029877527,0.045247186,0.1578455],"study_design_scores_gemma":[0.000029077155,0.0002090128,0.84185874,0.0031835923,0.0001964501,0.011113711,0.0048309285,0.00019320424,0.00021815918,0.002342782,0.13577877,0.000045648736],"about_ca_topic_score_codex":0.13946362,"about_ca_topic_score_gemma":0.21796702,"teacher_disagreement_score":0.8605364,"about_ca_system_score_codex":0.0021636619,"about_ca_system_score_gemma":0.003925461,"threshold_uncertainty_score":0.2773037},"labels":[],"label_agreement":null},{"id":"W4384134175","doi":"10.58931/cht.2023.2233","title":"Evolving role of novel therapies in myeloma: T-cell engagers and antibody-drug conjugates","year":2023,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University","funders":"","keywords":"Lenalidomide; Medicine; Daratumumab; Carfilzomib; Multiple myeloma; Pomalidomide; Thalidomide; Bortezomib; Internal medicine; Population; Oncology; Ixazomib; Proteasome inhibitor; Immunology","score_opus":0.017696681872267157,"score_gpt":0.2869579039078653,"score_spread":0.26926122203559816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384134175","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007707823,0.9466989,0.006293318,0.023896322,0.0027743147,0.000074771786,0.00020140459,0.00023156294,0.012121546],"genre_scores_gemma":[0.06520247,0.8844184,0.011648809,0.019579183,0.00459625,0.0002411653,0.0005153649,0.00008084993,0.013717558],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993198,0.00022719205,0.000038598733,0.000105235595,0.00020505801,0.00010412369],"domain_scores_gemma":[0.99897873,0.0004956528,0.000105345855,0.000033621527,0.0002001971,0.00018648236],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024772696,0.0006052554,0.00096522743,0.00078418496,0.00034917454,0.0023442751,0.000979187,0.0022479605,0.0056674755],"category_scores_gemma":[0.0017975098,0.00026202764,0.00066781195,0.00057256786,0.0011269598,0.0039252765,0.0015948822,0.0039348896,0.0022666643],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003990177,0.00046018575,0.0010051731,0.0028874993,0.00013661041,0.0005674691,0.0002457433,0.0020643526,0.017027264,0.05293012,0.07753044,0.84474605],"study_design_scores_gemma":[0.00016829038,0.0014948463,0.0007660459,0.00083019695,0.0000681295,0.0011758511,0.00016134752,0.0022246854,0.0065952665,0.019001361,0.9674664,0.00004759772],"about_ca_topic_score_codex":0.00036004765,"about_ca_topic_score_gemma":0.0009241236,"teacher_disagreement_score":0.0056674755,"about_ca_system_score_codex":0.0011196358,"about_ca_system_score_gemma":0.00078212144,"threshold_uncertainty_score":0.018959582},"labels":[],"label_agreement":null},{"id":"W4384134344","doi":"10.58931/cht.2023.2232","title":"Cellular therapy in CLL/iNHL: Therapeutic agents in the pipeline","year":2023,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Chimeric antigen receptor; Mantle cell lymphoma; Lymphoma; Chronic lymphocytic leukemia; Oncology; Refractory (planetary science); Immunology; Internal medicine; Immunotherapy; Leukemia; Immune system","score_opus":0.07791951657750991,"score_gpt":0.3436069837462599,"score_spread":0.26568746716875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384134344","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0051408345,0.8152458,0.0021959667,0.11585601,0.004329436,0.0001601872,0.0005457999,0.00030260498,0.05622338],"genre_scores_gemma":[0.03454001,0.89258915,0.0056520714,0.029721877,0.0030762956,0.00013731056,0.0008785458,0.00008752588,0.033317294],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991442,0.00012726779,0.00003494238,0.00006056746,0.000369912,0.00026309758],"domain_scores_gemma":[0.99797136,0.00027531618,0.00011105474,0.000043746775,0.0008669734,0.0007316086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021054307,0.0005748144,0.00064133754,0.0014621608,0.0012991404,0.0031189674,0.0008040755,0.0019376249,0.019941771],"category_scores_gemma":[0.0019037557,0.00017799038,0.00050101976,0.0014118925,0.001595154,0.0019158464,0.0017479914,0.0045581535,0.0039774105],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004547047,0.00033338685,0.0008138428,0.0011863713,0.000034293676,0.00043309637,0.00024861834,0.0006137103,0.0057792766,0.030889483,0.19604768,0.76316553],"study_design_scores_gemma":[0.00010123897,0.0002966922,0.0006616182,0.00061772804,0.00002719685,0.00028077824,0.000121901656,0.00021097355,0.0011585489,0.0026542814,0.9938543,0.00001476887],"about_ca_topic_score_codex":0.10318743,"about_ca_topic_score_gemma":0.25966838,"teacher_disagreement_score":0.10318743,"about_ca_system_score_codex":0.011087515,"about_ca_system_score_gemma":0.020291248,"threshold_uncertainty_score":0.20517367},"labels":[],"label_agreement":null},{"id":"W4384134428","doi":"10.58931/cht.2023.2124","title":"Tyrosine kinase inhibitors for the frontline management of CML: an overview","year":2023,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Bosutinib; Nilotinib; Dasatinib; Medicine; Imatinib; Ponatinib; Tyrosine kinase; Myeloid leukemia; Tyrosine-kinase inhibitor; Drug holiday; Internal medicine; Oncology; Population; Pharmacology; Immunology; Cancer","score_opus":0.04892717281739035,"score_gpt":0.31947437695510056,"score_spread":0.2705472041377102,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384134428","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00050740625,0.9905751,0.00038100118,0.002876956,0.00031059925,0.000018950508,0.000027447315,0.000015117022,0.0052875667],"genre_scores_gemma":[0.002058292,0.9944622,0.000878434,0.0009592746,0.0004910317,0.000013311134,0.000047873607,0.0000026225305,0.0010869679],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997732,0.00004168481,0.00002470471,0.00002385166,0.00010091491,0.000035632438],"domain_scores_gemma":[0.99973184,0.00008341774,0.000037290007,0.000004963122,0.00008969685,0.000052678035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059828634,0.00059083255,0.0004962027,0.0018524333,0.00035317976,0.0009875882,0.00048968906,0.0008611086,0.002962361],"category_scores_gemma":[0.0005095923,0.00014139935,0.0004652044,0.0012631821,0.00026037777,0.0011110626,0.00042495894,0.0019209892,0.0010751048],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010399766,0.00012853759,0.0005786744,0.003977493,0.00006282226,0.0004125031,0.00008187904,0.00023553107,0.0014257053,0.004277827,0.04546273,0.9432522],"study_design_scores_gemma":[0.000033035903,0.00022301439,0.001855333,0.0023475762,0.0001015901,0.0022577022,0.00006995963,0.00017427445,0.0003295725,0.0012636421,0.9913293,0.0000149407615],"about_ca_topic_score_codex":0.00314142,"about_ca_topic_score_gemma":0.014304284,"teacher_disagreement_score":0.00314142,"about_ca_system_score_codex":0.0011456911,"about_ca_system_score_gemma":0.0016775101,"threshold_uncertainty_score":0.009910047},"labels":[],"label_agreement":null},{"id":"W4384199314","doi":"10.58931/cht.2023.2125","title":"Venetoclax-based lower-intensity regimens for acute myeloid leukemia","year":2023,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Montréal; AstraZeneca (Canada); University of Toronto; University Health Network","funders":"University of Texas MD Anderson Cancer Center","keywords":"Venetoclax; Medicine; Azacitidine; Cytarabine; Myeloid leukemia; Internal medicine; Oncology; Decitabine; Chemotherapy; Leukemia; Chronic lymphocytic leukemia; DNA methylation","score_opus":0.026168025105676427,"score_gpt":0.3064412241498629,"score_spread":0.28027319904418646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384199314","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.58976203,0.32493755,0.008674948,0.0027649654,0.0010982739,0.0011347656,0.0021789635,0.0009521725,0.0684963],"genre_scores_gemma":[0.915772,0.05793337,0.0050620968,0.0025791063,0.00047968738,0.0003629285,0.003451673,0.000059561087,0.014299605],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999167,0.000027606406,0.0000050446943,0.000015874963,0.000020017029,0.000014818571],"domain_scores_gemma":[0.99989974,0.000021981432,0.00003259976,0.000008960234,0.0000084340345,0.000028295328],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015683753,0.00016153841,0.00033205742,0.00020580362,0.0001812803,0.00021216132,0.00023474627,0.00020296237,0.0049572163],"category_scores_gemma":[0.00029337758,0.000044700042,0.00021581068,0.00032292688,0.00010562187,0.00019004947,0.0002491489,0.0012004622,0.00095773],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052316505,0.001615045,0.0019821026,0.0010005282,0.00022462444,0.00020273225,0.000092672526,0.00093340245,0.018491916,0.0027837974,0.015674615,0.9517669],"study_design_scores_gemma":[0.021677483,0.03749221,0.09383191,0.0012547754,0.000774257,0.006979666,0.000103881735,0.003663634,0.018141026,0.0052786274,0.8107141,0.00008836176],"about_ca_topic_score_codex":0.0008184707,"about_ca_topic_score_gemma":0.002743974,"teacher_disagreement_score":0.0049572163,"about_ca_system_score_codex":0.00027830093,"about_ca_system_score_gemma":0.00018882248,"threshold_uncertainty_score":0.016583562},"labels":[],"label_agreement":null},{"id":"W4384199478","doi":"10.58931/cht.2023.2123","title":"Management of limited stage Hodgkin lymphoma","year":2023,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency; University of Saskatchewan","funders":"","keywords":"Stage (stratigraphy); Lymphoma; Medicine; Hodgkin lymphoma; Oncology; Internal medicine; Disease; Neoplasm; Lymphatic system; Pathology; Biology","score_opus":0.02175130596745079,"score_gpt":0.26964230744770595,"score_spread":0.24789100148025517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384199478","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.30508777,0.4335856,0.022711782,0.052882485,0.0029982368,0.0008653371,0.00082225754,0.0006826832,0.18036377],"genre_scores_gemma":[0.8325635,0.118920706,0.009660281,0.013523075,0.0034582394,0.00022928238,0.0011030056,0.00006959432,0.02047228],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998723,0.000018154371,0.000010993156,0.000015576847,0.00004215486,0.00004075799],"domain_scores_gemma":[0.9997986,0.000018407065,0.000023287736,0.000005476941,0.00004535461,0.000108925975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018996286,0.00017717406,0.0003043883,0.0003734877,0.00062831497,0.00051389355,0.00038587043,0.0004195757,0.0032006707],"category_scores_gemma":[0.00072949915,0.000054627708,0.00016790502,0.00026435705,0.00023824326,0.0003623078,0.00051897456,0.0007188959,0.00062199304],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003255254,0.000283859,0.03766116,0.0011592507,0.000059275375,0.025261195,0.0006161645,0.0008771367,0.009231712,0.0035590115,0.09529006,0.82567567],"study_design_scores_gemma":[0.00038976455,0.0014461533,0.12723604,0.0057160263,0.00022670785,0.17925802,0.0021651324,0.0026435326,0.0043763206,0.011973378,0.66447955,0.00008932761],"about_ca_topic_score_codex":0.009002599,"about_ca_topic_score_gemma":0.022437073,"teacher_disagreement_score":0.009002599,"about_ca_system_score_codex":0.0013549036,"about_ca_system_score_gemma":0.0013416576,"threshold_uncertainty_score":0.017900407},"labels":[],"label_agreement":null},{"id":"W4384199484","doi":"10.58931/cht.2023.2235","title":"Initiating venetoclax treatment: Clinical practice pearls","year":2023,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Red Deer Regional Hospital; University of Calgary","funders":"","keywords":"Venetoclax; Tumor lysis syndrome; Chronic lymphocytic leukemia; Medicine; Azacitidine; Myeloid leukemia; Lymphoma; Cancer research; Oncology; Leukemia; Internal medicine; Chemotherapy; Biology; DNA methylation","score_opus":0.08237989351488345,"score_gpt":0.4158169093391787,"score_spread":0.33343701582429525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384199484","genre_codex":"commentary","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0063683162,0.26110315,0.015186177,0.6320199,0.0059434883,0.00049507676,0.00067281903,0.0008780627,0.07733311],"genre_scores_gemma":[0.11591466,0.5035036,0.07875347,0.24414147,0.024341928,0.0010596957,0.0017696436,0.00068574725,0.029829793],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977233,0.0007142339,0.00032259765,0.00020775662,0.0008909782,0.00014119374],"domain_scores_gemma":[0.99307257,0.0018115019,0.0006744467,0.0002087114,0.0022805915,0.0019523135],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034261718,0.0005255217,0.0007544535,0.001399655,0.0016920721,0.004125404,0.0016849923,0.002862119,0.012100773],"category_scores_gemma":[0.015519193,0.0002643974,0.00053840905,0.0010988959,0.00092679844,0.002614107,0.0013248603,0.0073378165,0.004376787],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012919132,0.00022013017,0.002992741,0.0008459092,0.000031366257,0.0011175333,0.00042094797,0.00052724406,0.00042358023,0.0046379766,0.28089708,0.7077563],"study_design_scores_gemma":[0.00017805595,0.00026507932,0.008969604,0.009919597,0.000075643766,0.0059332238,0.0015946652,0.00083687186,0.00052247755,0.02097849,0.95061415,0.000112198184],"about_ca_topic_score_codex":0.015916688,"about_ca_topic_score_gemma":0.043774165,"teacher_disagreement_score":0.015916688,"about_ca_system_score_codex":0.0043521817,"about_ca_system_score_gemma":0.00846352,"threshold_uncertainty_score":0.04048115},"labels":[],"label_agreement":null},{"id":"W4384199598","doi":"10.58931/cht.2023.2234","title":"Acute myeloid leukemia induction in the age of novel therapeutic agents","year":2023,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nova Scotia Health Authority; Dalhousie University","funders":"","keywords":"Medicine; Cytarabine; Idarubicin; Myeloid leukemia; Oncology; Internal medicine; Myeloid; Anthracycline; Daunorubicin; Transplantation; Disease; Leukemia; Intensive care medicine; Cancer","score_opus":0.05621292049936643,"score_gpt":0.3244565945704068,"score_spread":0.2682436740710404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384199598","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16604699,0.6304675,0.026470363,0.033394005,0.0076777097,0.00084721786,0.0011243375,0.001106919,0.132865],"genre_scores_gemma":[0.57704496,0.3295535,0.018068649,0.018721705,0.0049036415,0.0008968302,0.0019460496,0.00014544945,0.048719272],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99972886,0.00006439049,0.000022040118,0.000048345653,0.00007771607,0.000058634974],"domain_scores_gemma":[0.9997644,0.000049601065,0.00005995974,0.000021638578,0.000052753854,0.000051690942],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005655907,0.00032813003,0.0006419674,0.000243715,0.00024409221,0.00087574305,0.00046917525,0.0006372811,0.004042942],"category_scores_gemma":[0.0005907037,0.00013754336,0.00045320988,0.0002122641,0.00029075428,0.0009164874,0.0008813038,0.0021269277,0.0018692403],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019201195,0.0011691306,0.0036299082,0.0025642829,0.00015589788,0.0013515025,0.00032417936,0.0013980082,0.10370703,0.031114409,0.057278395,0.79538727],"study_design_scores_gemma":[0.00048527517,0.002989836,0.004266229,0.0007518988,0.00015329843,0.003779159,0.00009104885,0.001087813,0.036550596,0.008438924,0.94136554,0.000040404688],"about_ca_topic_score_codex":0.0001726555,"about_ca_topic_score_gemma":0.0005114711,"teacher_disagreement_score":0.004042942,"about_ca_system_score_codex":0.0005576828,"about_ca_system_score_gemma":0.0004527934,"threshold_uncertainty_score":0.013525009},"labels":[],"label_agreement":null},{"id":"W4384274087","doi":"10.58931/cht.2022.1317","title":"The evolving treatment landscape of higher-risk MDS","year":2022,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Cytopenia; Myelodysplastic syndromes; Incidence (geometry); Myeloid leukemia; Medicine; Internal medicine; Oncology; Dysplasia; Leukemia; Bone marrow","score_opus":0.014492270602639908,"score_gpt":0.27283858115351917,"score_spread":0.25834631055087925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384274087","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.031683397,0.32908735,0.0035997187,0.58355874,0.0028846704,0.000055663906,0.0006420633,0.00017173214,0.04831672],"genre_scores_gemma":[0.37013632,0.4462026,0.010450642,0.13884765,0.022276556,0.0002471299,0.002014592,0.00037477806,0.0094496785],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99739563,0.00075205945,0.0002779533,0.00035227413,0.00086691463,0.0003551773],"domain_scores_gemma":[0.99419075,0.0012277048,0.0006281249,0.00011404464,0.0017489028,0.0020903468],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044278023,0.00024917978,0.0006887242,0.0010459039,0.0011899173,0.0028585992,0.0010443103,0.0014442997,0.0066887946],"category_scores_gemma":[0.00989983,0.00016665421,0.00047277063,0.0011458003,0.0014501059,0.0017604731,0.0019255319,0.003801087,0.001339623],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003893163,0.00015502557,0.010609155,0.0009219683,0.000082177976,0.00087372615,0.0010663101,0.0016671794,0.0016406422,0.030409742,0.14032124,0.8118636],"study_design_scores_gemma":[0.000120607954,0.00044304432,0.018568877,0.0029122469,0.000098862765,0.004138642,0.0021745558,0.00085176405,0.0006929735,0.022972167,0.9469446,0.000081619415],"about_ca_topic_score_codex":0.010486602,"about_ca_topic_score_gemma":0.028549183,"teacher_disagreement_score":0.010486602,"about_ca_system_score_codex":0.0070478767,"about_ca_system_score_gemma":0.009355996,"threshold_uncertainty_score":0.051136136},"labels":[],"label_agreement":null},{"id":"W4384274089","doi":"10.58931/cht.2022.1316","title":"Moving beyond chemotherapy in the management of follicular lymphoma","year":2022,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Rituximab; Medicine; Regimen; Follicular lymphoma; Bendamustine; Internal medicine; Oncology; Chemotherapy; Lymphoma; Chemotherapy regimen; Induction chemotherapy; Surgery","score_opus":0.00916739963115653,"score_gpt":0.23730394450874662,"score_spread":0.22813654487759008,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384274089","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02212323,0.68691814,0.0034949793,0.16426165,0.0051930128,0.00021916632,0.0002504527,0.0001437251,0.117395684],"genre_scores_gemma":[0.24326059,0.589216,0.011686654,0.10571727,0.013139793,0.00020122922,0.000732888,0.00014645784,0.035899144],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995515,0.00010356426,0.000027796643,0.00004549691,0.00017460968,0.00009711932],"domain_scores_gemma":[0.999087,0.00020777172,0.00010890234,0.00002365763,0.00026490955,0.0003078208],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00081622886,0.00025604817,0.00040742432,0.00058643945,0.00074806187,0.0010502032,0.0006701787,0.0010959535,0.0049718227],"category_scores_gemma":[0.001743031,0.00006377706,0.00033060502,0.00052171084,0.00068648736,0.0008065512,0.00075129344,0.00221966,0.0010973754],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046752885,0.00016010215,0.0028422473,0.0011586165,0.000068057816,0.00091275154,0.00027098742,0.0009762318,0.0017565546,0.0076218056,0.1129276,0.87083745],"study_design_scores_gemma":[0.0002544219,0.0004886417,0.0076815393,0.0023944464,0.00007476189,0.002131353,0.00022602052,0.00039049346,0.00048579113,0.004814125,0.98103,0.00002835826],"about_ca_topic_score_codex":0.054335907,"about_ca_topic_score_gemma":0.17025775,"teacher_disagreement_score":0.054335907,"about_ca_system_score_codex":0.00670466,"about_ca_system_score_gemma":0.0046630637,"threshold_uncertainty_score":0.10803926},"labels":[],"label_agreement":null},{"id":"W4384274095","doi":"10.58931/cht.2022.1320","title":"Chronic Myeloid Leukemia: who should get a treatment-free trial and how?","year":2022,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Myeloid leukemia; Discontinuation; Chronic myelogenous leukemia; Life expectancy; Clinical trial; Oncology; Internal medicine; Quality of life (healthcare); Leukemia; Intensive care medicine; Population; Nursing","score_opus":0.02688000657122393,"score_gpt":0.2643091174620462,"score_spread":0.23742911089082228,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384274095","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006036325,0.04440042,0.0005270736,0.9325104,0.010384714,0.00037109162,0.0004538487,0.00008603444,0.010662864],"genre_scores_gemma":[0.016869107,0.06058858,0.010304255,0.8525995,0.032846946,0.0026850984,0.0011828057,0.0002737685,0.022649867],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9729725,0.015438826,0.0026415852,0.0015144009,0.005087646,0.0023450153],"domain_scores_gemma":[0.88723505,0.03548014,0.0069488813,0.003889061,0.024410658,0.042036198],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.056393,0.0007112205,0.0034280415,0.0017574866,0.0049238116,0.015117369,0.0033180474,0.016997933,0.032071117],"category_scores_gemma":[0.1303203,0.00059323275,0.0016257409,0.0024360768,0.007172456,0.013929894,0.0033687092,0.009276932,0.012645216],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008072436,0.00016496853,0.0015887322,0.0018517786,0.00009651277,0.00011435615,0.00032539485,0.0000912561,0.00015832101,0.011811862,0.7539699,0.22901964],"study_design_scores_gemma":[0.0019807513,0.00021296625,0.0017403578,0.0063298987,0.00012993645,0.00015708254,0.0006592686,0.00015827532,0.000098535806,0.01845478,0.9699836,0.00009455676],"about_ca_topic_score_codex":0.056569353,"about_ca_topic_score_gemma":0.119325645,"teacher_disagreement_score":0.056569353,"about_ca_system_score_codex":0.016431345,"about_ca_system_score_gemma":0.0603356,"threshold_uncertainty_score":0.29823822},"labels":[],"label_agreement":null},{"id":"W4384383301","doi":"10.58931/cht.2023.2121","title":"Frontline management of transplant-ineligible newly diagnosed multiple myeloma (TINDMM) in Canada","year":2023,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Northern British Columbia; University of British Columbia; BC Cancer Agency","funders":"BC Cancer Agency","keywords":"Medicine; Multiple myeloma; Malignancy; Hematologic malignancy; Anemia; Bone marrow transplant; Bone marrow; Internal medicine; Pediatrics; Bone marrow transplantation","score_opus":0.020733173375689404,"score_gpt":0.26435175282128953,"score_spread":0.24361857944560011,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384383301","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.48651588,0.049082637,0.0020818035,0.20270444,0.0026369623,0.0008321368,0.0066876244,0.0003283548,0.24913022],"genre_scores_gemma":[0.8975543,0.028730175,0.00442653,0.036051232,0.0006135769,0.00011435703,0.0028801742,0.000091266455,0.029538251],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99953496,0.000028710327,0.000020697462,0.000038920123,0.00015094712,0.0002257779],"domain_scores_gemma":[0.9980578,0.000042317282,0.00015265147,0.000010787372,0.00042904538,0.0013074493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002875142,0.00014179306,0.00022959775,0.00060786615,0.0038176316,0.0011064496,0.0009590846,0.0005028316,0.009027269],"category_scores_gemma":[0.0012761105,0.0001105652,0.00026121573,0.0011372603,0.00045959497,0.0003445714,0.0009967231,0.001229256,0.00054823275],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00058975135,0.00059750606,0.33421874,0.0008410186,0.00012204115,0.009495721,0.0025132708,0.00090247224,0.002665413,0.008562179,0.3392536,0.30023828],"study_design_scores_gemma":[0.00035398162,0.00031651044,0.50828636,0.0024761173,0.00015967716,0.008245236,0.008152883,0.0020688656,0.00082374545,0.0032274919,0.46577066,0.00011845158],"about_ca_topic_score_codex":0.9561937,"about_ca_topic_score_gemma":0.9883122,"teacher_disagreement_score":0.043806314,"about_ca_system_score_codex":0.032034326,"about_ca_system_score_gemma":0.06836136,"threshold_uncertainty_score":0.23242635},"labels":[],"label_agreement":null},{"id":"W4384383362","doi":"10.58931/cht.2023.2122","title":"Controversies and current practices in CNS relapse of diffuse large B-cell lymphoma","year":2022,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"CNS Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Occult; Context (archaeology); Lymphoma; Diffuse large B-cell lymphoma; Central nervous system; Complication; Disease; Oncology; Intensive care medicine; Internal medicine; Pathology; Alternative medicine","score_opus":0.01628989550876234,"score_gpt":0.2702774122670832,"score_spread":0.2539875167583208,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384383362","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017457636,0.752925,0.0014955053,0.23209077,0.0062390976,0.000023560338,0.00007905302,0.000058636502,0.00534274],"genre_scores_gemma":[0.040623307,0.85641414,0.0049537728,0.0732757,0.023039488,0.000075336975,0.00020174473,0.000069535585,0.0013469975],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99269944,0.0030564289,0.0014778338,0.0007197834,0.0016250252,0.00042156555],"domain_scores_gemma":[0.9670379,0.019933032,0.0020733203,0.0007835894,0.008350499,0.0018216948],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014870374,0.0005247556,0.0014017733,0.002999829,0.0022855154,0.0048048384,0.0030084234,0.0032570672,0.0027485108],"category_scores_gemma":[0.037871834,0.00038534217,0.0008914856,0.0029186471,0.006368903,0.005472232,0.0026184043,0.00866306,0.0012163491],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018385622,0.000101672544,0.0058555207,0.0077627217,0.00016081311,0.0011304251,0.0032621215,0.00045329088,0.00045027919,0.021639034,0.20423836,0.75476193],"study_design_scores_gemma":[0.000054815144,0.00009283201,0.0046704696,0.023641288,0.000296715,0.004410797,0.0073008593,0.00039807145,0.0005059929,0.03821754,0.9202917,0.000118920245],"about_ca_topic_score_codex":0.019917754,"about_ca_topic_score_gemma":0.03010587,"teacher_disagreement_score":0.019917754,"about_ca_system_score_codex":0.0057096905,"about_ca_system_score_gemma":0.010852138,"threshold_uncertainty_score":0.078643024},"labels":[],"label_agreement":null},{"id":"W4384383449","doi":"10.58931/cht.2022.1319","title":"Hereditary hematologic malignancies: a Canadian perspective","year":2022,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"CEBPA; Germline; Genetic predisposition; Malignancy; Myeloid; Platelet disorder; Medicine; ETV6; Germline mutation; Cancer; GATA2; Genetics; Immunology; Biology; Mutation; Internal medicine; Gene; Disease; Chromosomal translocation; Platelet","score_opus":0.01887377594990247,"score_gpt":0.2717560610194565,"score_spread":0.252882285069554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384383449","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0066337395,0.35679817,0.00066348724,0.5467526,0.0078075933,0.000039194063,0.00062583847,0.00007937006,0.08060009],"genre_scores_gemma":[0.089021586,0.758361,0.0023672439,0.122111395,0.010867391,0.000031684594,0.00039237557,0.00007923238,0.016768146],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.998396,0.00015590937,0.00012049109,0.00022322786,0.0007163225,0.00038808817],"domain_scores_gemma":[0.9914262,0.0007384398,0.0002715755,0.00009892425,0.0045373007,0.002927531],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018688536,0.0006495224,0.0007920593,0.0035421771,0.0061996523,0.0028893077,0.0016669488,0.00377451,0.011961532],"category_scores_gemma":[0.0052219434,0.00037585504,0.0004764139,0.004254476,0.0039949617,0.0020576036,0.0017773837,0.006205757,0.0012845674],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010684229,0.000110530906,0.01596122,0.0012272793,0.00008075085,0.01624617,0.0040537086,0.00042016644,0.00097304827,0.048372913,0.6993125,0.21313491],"study_design_scores_gemma":[0.00003141444,0.0000338283,0.0108087985,0.002809886,0.00007524558,0.015130214,0.004655266,0.00016448913,0.00010577511,0.0063832365,0.9597057,0.00009605718],"about_ca_topic_score_codex":0.91715515,"about_ca_topic_score_gemma":0.9531489,"teacher_disagreement_score":0.08284485,"about_ca_system_score_codex":0.043441467,"about_ca_system_score_gemma":0.07465124,"threshold_uncertainty_score":0.3151914},"labels":[],"label_agreement":null},{"id":"W4384460914","doi":"10.58931/cht.2023.2s0736","title":"Navigating challenging treatment decisions in relapsed and refractory multiple myeloma (RRMM)","year":2023,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Sherbrooke; London Health Sciences Centre; Western University","funders":"University of British Columbia; University of Ottawa; University of Alberta; University of Calgary","keywords":"Medicine; Multiple myeloma; Intensive care medicine; Refractory (planetary science); Oncology; Clinical trial; Internal medicine","score_opus":0.0474630905079517,"score_gpt":0.3348810642120623,"score_spread":0.2874179737041106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384460914","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0422425,0.04576036,0.014205344,0.85739404,0.004317938,0.00028547543,0.00047582618,0.000303369,0.035015155],"genre_scores_gemma":[0.5895736,0.0801602,0.07758879,0.22902815,0.01378067,0.00049822254,0.0011308255,0.0005415452,0.0076979958],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98476934,0.01004922,0.00077514997,0.0011084023,0.0017846395,0.0015133182],"domain_scores_gemma":[0.9623794,0.017878415,0.0038663438,0.00062320766,0.004321665,0.010930946],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01811217,0.00046659802,0.0015456245,0.0016250731,0.00734144,0.01139256,0.0023241309,0.0043106154,0.0074283336],"category_scores_gemma":[0.06549944,0.00062353804,0.0010382783,0.0014466619,0.0046237824,0.005759687,0.006961475,0.014794066,0.0018063035],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006368804,0.00044954722,0.022226328,0.0014005265,0.00044763534,0.0028403427,0.011085952,0.004830406,0.0006670352,0.03357073,0.4344966,0.4873481],"study_design_scores_gemma":[0.00040616913,0.00056411704,0.014998771,0.005438119,0.00045357985,0.003626682,0.031270977,0.007394714,0.0008906314,0.35355556,0.5809082,0.0004925763],"about_ca_topic_score_codex":0.029053183,"about_ca_topic_score_gemma":0.078508854,"teacher_disagreement_score":0.9709468,"about_ca_system_score_codex":0.0105193835,"about_ca_system_score_gemma":0.039164465,"threshold_uncertainty_score":0.095787466},"labels":[],"label_agreement":null},{"id":"W4384461310","doi":"10.58931/cht.2023.2s0326","title":"A review of the mechanism of action, safety, and efficacy of selinexor in multiple myeloma","year":2023,"lang":"en","type":"review","venue":"Canadian Hematology Today","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Lenalidomide; Carfilzomib; Bortezomib; Pomalidomide; Multiple myeloma; Medicine; Dexamethasone; Oncology; Pharmacology; Mechanism of action; Drug; Internal medicine; Chemistry","score_opus":0.09048699920866078,"score_gpt":0.37222517905179714,"score_spread":0.28173817984313637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384461310","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014557375,0.9988342,0.00007320034,0.00014635341,0.00012358067,0.000007934156,0.000033643635,0.0000056036215,0.000629869],"genre_scores_gemma":[0.0006543125,0.9983924,0.00015954778,0.00023255813,0.0001466748,0.000010876235,0.00004521275,0.0000014297584,0.0003569581],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997334,0.00005096991,0.000068998466,0.00004462436,0.00008497849,0.000017007453],"domain_scores_gemma":[0.9995664,0.00024536677,0.00008504909,0.0000086508335,0.000073217685,0.000021379758],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006716266,0.0006769894,0.0014163111,0.0021892793,0.00024160613,0.00085792935,0.00071886095,0.00066699024,0.0042757355],"category_scores_gemma":[0.0010313513,0.00032848437,0.0011077073,0.0018040661,0.0002531805,0.0010310815,0.00039516715,0.0012424713,0.001183552],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022044133,0.00011349674,0.00022432336,0.079534985,0.0003238193,0.00031301955,0.0001243923,0.00045693715,0.0025839428,0.0018885382,0.039180364,0.8750358],"study_design_scores_gemma":[0.000044200915,0.0003976501,0.0014077988,0.017172711,0.0006141212,0.0016147136,0.000055694254,0.00011436071,0.00053701014,0.0008413645,0.9771722,0.000028240414],"about_ca_topic_score_codex":0.0011191794,"about_ca_topic_score_gemma":0.0018959605,"teacher_disagreement_score":0.9988808,"about_ca_system_score_codex":0.00048181642,"about_ca_system_score_gemma":0.0008942347,"threshold_uncertainty_score":0.014303744},"labels":[],"label_agreement":null},{"id":"W4384461365","doi":"10.58931/cht.2022.1s1029","title":"Treatment options for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) patients","year":2022,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Centre Hospitalier de l’Université de Montréal; Cégep de l'Abitibi Témiscamingue; Juravinski Cancer Centre; Université du Québec en Abitibi-Témiscamingue","funders":"Canadian Institutes of Health Research; Canadian Breast Cancer Research Alliance","keywords":"Diffuse large B-cell lymphoma; Medicine; Lymphoma; Oncology; Refractory (planetary science); Adverse effect; Internal medicine; Intensive care medicine","score_opus":0.012985825229573462,"score_gpt":0.24204650729152016,"score_spread":0.2290606820619467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384461365","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.101917274,0.6796062,0.006817203,0.069580734,0.0018803122,0.00030051198,0.0020435874,0.0003532604,0.13750087],"genre_scores_gemma":[0.60710466,0.32513693,0.008926464,0.02837201,0.0037212952,0.00038895675,0.0044014654,0.00009913163,0.021849098],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99989545,0.000022404023,0.000011686832,0.000012210795,0.000028147611,0.00003007084],"domain_scores_gemma":[0.99987113,0.000028669301,0.000021554484,0.0000031953998,0.00001639297,0.000058979505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019906333,0.00015714261,0.00037015113,0.00035903516,0.00040460008,0.00052701606,0.00034646294,0.00046750114,0.008897993],"category_scores_gemma":[0.0004590089,0.000056768993,0.0003675885,0.0002655134,0.000160619,0.00041110595,0.00033851035,0.001065123,0.0014444456],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011221824,0.00035515463,0.0076694232,0.0014922175,0.0001406226,0.0029687202,0.0002396464,0.0011659284,0.004943709,0.0038443916,0.12579443,0.8502636],"study_design_scores_gemma":[0.0011360937,0.0013539653,0.029923238,0.0040817643,0.00039063094,0.019458385,0.0007879964,0.0012563447,0.0027410714,0.012573979,0.92624044,0.000056025972],"about_ca_topic_score_codex":0.0016395809,"about_ca_topic_score_gemma":0.005860683,"teacher_disagreement_score":0.008897993,"about_ca_system_score_codex":0.0005293657,"about_ca_system_score_gemma":0.0005640832,"threshold_uncertainty_score":0.029766738},"labels":[],"label_agreement":null},{"id":"W4384461377","doi":"10.58931/cht.2022.1s1227","title":"Updates in the treatment of mantle cell lymphoma: A Canadian expert framework","year":2022,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"BeiGene; Royal College of Physicians and Surgeons of Canada; Bristol-Myers Squibb; Canadian Hematology Society; AstraZeneca; Celgene; Gilead Sciences","keywords":"Mantle cell lymphoma; Blastoid; IGHV@; Lymphoma; Bone marrow; Cancer research; Lymph node; Medicine; Follicular lymphoma; Biology; Oncology; Internal medicine; Chronic lymphocytic leukemia; Leukemia","score_opus":0.01419186452329993,"score_gpt":0.2532317796375717,"score_spread":0.23903991511427178,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384461377","genre_codex":"review","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00059413374,0.6316273,0.0014993415,0.31801853,0.016515383,0.00015696893,0.00059918774,0.00025775316,0.030731509],"genre_scores_gemma":[0.0082115745,0.8169724,0.010027797,0.12377896,0.019400587,0.0001796058,0.0019394136,0.00018961617,0.01929999],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9949826,0.0007919286,0.00056088605,0.0003983159,0.002489877,0.000776341],"domain_scores_gemma":[0.97144747,0.0029544798,0.0012443208,0.00033659503,0.019118063,0.004898987],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010884017,0.0011121666,0.0016410999,0.0032722375,0.0022461035,0.004014762,0.004761681,0.006579055,0.015084511],"category_scores_gemma":[0.017125186,0.00048202107,0.0018471956,0.0031047226,0.002217724,0.0035932304,0.003233995,0.010502977,0.0048507443],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000108474014,0.00007579744,0.00040215443,0.0018250204,0.000047194626,0.00020493697,0.00017504088,0.00050032727,0.00041524795,0.0042837565,0.58696485,0.4049972],"study_design_scores_gemma":[0.000031425392,0.000035472633,0.0004397933,0.0035189001,0.000040391737,0.00019994799,0.000075614924,0.000088136374,0.000061670275,0.0010489307,0.9944384,0.00002133582],"about_ca_topic_score_codex":0.27496725,"about_ca_topic_score_gemma":0.46768263,"teacher_disagreement_score":0.72503275,"about_ca_system_score_codex":0.023652906,"about_ca_system_score_gemma":0.049266562,"threshold_uncertainty_score":0.5467335},"labels":[],"label_agreement":null},{"id":"W4384463905","doi":"10.58931/cht.2022.116","title":"Management of follicular lymphoma at first relapse","year":2022,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Follicular lymphoma; Lymphoma; Medicine; Oncology; Internal medicine; Follicular phase; Disease","score_opus":0.009802149988350896,"score_gpt":0.22303070448951995,"score_spread":0.21322855450116907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384463905","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.58209264,0.17787999,0.027744366,0.030362777,0.002521135,0.0010838583,0.00097244035,0.0015794686,0.17576343],"genre_scores_gemma":[0.9403492,0.024747366,0.0061357683,0.0069937445,0.0023908217,0.00021934255,0.001015331,0.00014588292,0.018002495],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997019,0.000035834422,0.000023388997,0.00003195385,0.00008502705,0.00012192253],"domain_scores_gemma":[0.9996418,0.000031614603,0.000047036126,0.000016159618,0.00008783944,0.00017559605],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034005326,0.00033981976,0.0006430206,0.0007223202,0.0010617635,0.0007795774,0.00072851405,0.0009535022,0.0031530245],"category_scores_gemma":[0.0011899961,0.00009929958,0.00043275792,0.00023296585,0.00026446217,0.00055053656,0.0006970539,0.0013823247,0.0013216704],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00089651754,0.0005144836,0.07693042,0.000896933,0.00012333729,0.11051912,0.001703959,0.0015590441,0.022491166,0.0032304316,0.08549517,0.6956395],"study_design_scores_gemma":[0.00029417983,0.0023897877,0.17393011,0.003566034,0.0003168691,0.45662284,0.0032959592,0.0046083275,0.015021853,0.010476436,0.3292821,0.00019550392],"about_ca_topic_score_codex":0.0050047985,"about_ca_topic_score_gemma":0.006573139,"teacher_disagreement_score":0.0050047985,"about_ca_system_score_codex":0.001671849,"about_ca_system_score_gemma":0.0010148576,"threshold_uncertainty_score":0.012130201},"labels":[],"label_agreement":null},{"id":"W4384463907","doi":"10.58931/cht.2022.117","title":"Myeloproliferative neoplasms in 2022","year":2022,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital","funders":"","keywords":"Polycythemia vera; Essential thrombocythemia; Ruxolitinib; Myelofibrosis; Myeloid leukemia; Medicine; Janus kinase 2; Oncology; Disease; Janus kinase; Internal medicine; Stem cell; Haematopoiesis; Immunology; Myeloproliferative Disorders; Myeloproliferative neoplasm; Myeloid; Cancer research; Bone marrow; Biology; Cytokine; Receptor","score_opus":0.011950200826081201,"score_gpt":0.2499592666882276,"score_spread":0.2380090658621464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384463907","genre_codex":"other","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15248959,0.069299504,0.0018843887,0.012469388,0.0034416397,0.0005052347,0.0046373866,0.00035774882,0.75491524],"genre_scores_gemma":[0.65547144,0.03272657,0.0028017124,0.00931311,0.002352548,0.00021050088,0.0056687538,0.00006086031,0.2913945],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99987113,0.000012249289,0.000008771504,0.000011956365,0.000049122784,0.00004671428],"domain_scores_gemma":[0.99985254,0.000013265504,0.000016803571,0.000005251472,0.000043069886,0.00006912472],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014299291,0.00022915314,0.00015695632,0.00056563545,0.0007479132,0.00051123474,0.00016140491,0.00044135682,0.029359054],"category_scores_gemma":[0.00046938437,0.000062346524,0.00011364749,0.0005567834,0.00017846383,0.00023603161,0.00042326053,0.0004474163,0.0060338685],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053638476,0.00033240754,0.1022902,0.0006965153,0.000037909515,0.043258633,0.0006243351,0.00021980837,0.010355369,0.016331036,0.22492395,0.6003935],"study_design_scores_gemma":[0.000053149935,0.0000941827,0.06845712,0.0003770728,0.000023322638,0.06595727,0.00030597506,0.00011649459,0.0014287619,0.0018215332,0.86135393,0.000011250505],"about_ca_topic_score_codex":0.00935619,"about_ca_topic_score_gemma":0.019789238,"teacher_disagreement_score":0.029359054,"about_ca_system_score_codex":0.00083522836,"about_ca_system_score_gemma":0.001667072,"threshold_uncertainty_score":0.09821576},"labels":[],"label_agreement":null},{"id":"W4384463912","doi":"10.58931/cht.2022.1211","title":"Immunotherapy in Hodgkin lymphoma","year":2022,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Brentuximab vedotin; Medicine; Pembrolizumab; Nivolumab; Oncology; Internal medicine; Lymphoma; Clinical trial; Malignancy; Immunotherapy; Chemotherapy; Cancer; Hodgkin lymphoma","score_opus":0.011063780678619472,"score_gpt":0.2438885588094986,"score_spread":0.23282477813087915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384463912","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013554754,0.9270723,0.0010414196,0.019579202,0.0033163542,0.0000758294,0.00010924881,0.00007461391,0.03517641],"genre_scores_gemma":[0.13939016,0.8137335,0.0024320725,0.019266976,0.008283754,0.00019719533,0.00037892692,0.00002009107,0.016297294],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999788,0.000069621194,0.000017743661,0.000019018787,0.000052830466,0.000052843217],"domain_scores_gemma":[0.999806,0.00006855914,0.000028840905,0.000010695741,0.000039781207,0.000046113353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000572279,0.00022243185,0.00037080082,0.00050461147,0.00036259872,0.0005476145,0.00026375483,0.0009102967,0.0035602956],"category_scores_gemma":[0.00056063116,0.00010195102,0.000288993,0.000417173,0.00038438058,0.00047533863,0.00043072214,0.0013293251,0.0010591435],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037616413,0.00038031195,0.003308971,0.0022007818,0.00006749212,0.0014413252,0.00016323493,0.0008024838,0.0066016624,0.01425698,0.085131615,0.8852691],"study_design_scores_gemma":[0.0003306484,0.00075979944,0.005585376,0.0013557981,0.0000651371,0.005872759,0.00010993989,0.00037674938,0.0022833808,0.008354331,0.9748872,0.000018982735],"about_ca_topic_score_codex":0.0017720449,"about_ca_topic_score_gemma":0.003548789,"teacher_disagreement_score":0.0035602956,"about_ca_system_score_codex":0.0012985813,"about_ca_system_score_gemma":0.0012609089,"threshold_uncertainty_score":0.011910379},"labels":[],"label_agreement":null},{"id":"W4384463914","doi":"10.58931/cht.2022.1215","title":"With great power comes great responsibility: Managing side effects of novel treatments in chronic lymphocytic leukemia (CLL)","year":2022,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; Internal medicine; Oncology; Hematologist; Rating scale; Clinical trial; Intensive care medicine; Leukemia; Psychology; Disease","score_opus":0.013766826476670749,"score_gpt":0.27012322071496603,"score_spread":0.25635639423829526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384463914","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08026915,0.3951425,0.019948058,0.41066653,0.004483145,0.0003474626,0.0003464691,0.0005706658,0.08822602],"genre_scores_gemma":[0.6277093,0.23087752,0.039305605,0.06856138,0.010323064,0.00037835355,0.00044918468,0.00028414387,0.022111421],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963595,0.0018855592,0.00023127197,0.00015202013,0.0011635814,0.0002080647],"domain_scores_gemma":[0.9915889,0.0037052275,0.0015403043,0.00029472663,0.001646536,0.0012242775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0066932733,0.00031560898,0.0007204085,0.00060987956,0.0012585572,0.002979497,0.0007122407,0.0010701302,0.0035124228],"category_scores_gemma":[0.018905673,0.00012910816,0.00050569006,0.00055098935,0.0011829128,0.0018538905,0.0013538046,0.0030513927,0.0008371374],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041912263,0.0002233113,0.010471064,0.00068768195,0.00016071845,0.00059690233,0.0006421514,0.000695117,0.000982581,0.003625646,0.07158637,0.90990937],"study_design_scores_gemma":[0.00073804456,0.0036020703,0.072867334,0.0053531164,0.00081311935,0.008764725,0.0036882365,0.0045881635,0.0037321465,0.04752694,0.8480701,0.00025598335],"about_ca_topic_score_codex":0.0048466604,"about_ca_topic_score_gemma":0.01811022,"teacher_disagreement_score":0.0066932733,"about_ca_system_score_codex":0.0024993727,"about_ca_system_score_gemma":0.0054393914,"threshold_uncertainty_score":0.035397828},"labels":[],"label_agreement":null},{"id":"W4384463921","doi":"10.58931/cht.2022.1214","title":"Chimeric antigen receptor T-cell therapy for relapsed and refractory large B-cell lymphoma","year":2022,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Chemoimmunotherapy; Medicine; Rituximab; Lymphoma; Vincristine; Internal medicine; Oncology; Cyclophosphamide; Chemotherapy; Refractory (planetary science); Salvage therapy; Prednisone; CHOP; Autologous stem-cell transplantation","score_opus":0.01717987800143865,"score_gpt":0.27041674975359287,"score_spread":0.2532368717521542,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384463921","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6749475,0.1622351,0.009782253,0.013224996,0.0024444438,0.000964988,0.0009816404,0.0016374685,0.1337817],"genre_scores_gemma":[0.9499873,0.026174454,0.0027775113,0.002986321,0.00040544785,0.00016269211,0.001077275,0.000055236243,0.016373804],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999274,0.000013176469,0.000002643061,0.0000060063007,0.000024063567,0.000026677631],"domain_scores_gemma":[0.9999436,0.000006935352,0.0000071368368,0.0000045084284,0.000011241813,0.000026613672],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022415568,0.00018215511,0.00032516418,0.00030492072,0.0003100327,0.00025972148,0.00033782364,0.00036327148,0.003961583],"category_scores_gemma":[0.00018154165,0.000046147325,0.00026176768,0.00026806566,0.00020021303,0.0001769917,0.00016624363,0.00070970826,0.0010548403],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036482783,0.0015226457,0.0034427107,0.0005499033,0.00020455007,0.0036859224,0.00019407383,0.0016703849,0.031152664,0.0030104127,0.06705559,0.883863],"study_design_scores_gemma":[0.014419912,0.021555496,0.08560919,0.0005322147,0.00047253797,0.024822649,0.00037014665,0.010846474,0.028156227,0.00473971,0.8083688,0.000106626845],"about_ca_topic_score_codex":0.011695055,"about_ca_topic_score_gemma":0.028996771,"teacher_disagreement_score":0.011695055,"about_ca_system_score_codex":0.0014040907,"about_ca_system_score_gemma":0.0008051996,"threshold_uncertainty_score":0.023253977},"labels":[],"label_agreement":null},{"id":"W4384463934","doi":"10.58931/cht.2022.1213","title":"Multiple myeloma management: What comes after lenalidomide-based therapy?","year":2022,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Lenalidomide; Multiple myeloma; Medicine; Monoclonal antibody; Quality of life (healthcare); Oncology; Internal medicine; Pharmacology; Antibody; Immunology","score_opus":0.02060857983614805,"score_gpt":0.2658410217929562,"score_spread":0.24523244195680816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384463934","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014216485,0.7696528,0.0005041961,0.21730438,0.007354976,0.000022012466,0.00009503523,0.000049404975,0.003595514],"genre_scores_gemma":[0.02294503,0.81554836,0.0019387787,0.102380775,0.054786436,0.000057730624,0.00025188757,0.00005871815,0.0020323198],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967944,0.0009923737,0.000483411,0.0003256241,0.0010338853,0.00037033632],"domain_scores_gemma":[0.9875618,0.0052896803,0.00095348817,0.00022754492,0.003872754,0.0020947042],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0070086955,0.0008116574,0.0034908643,0.0014922651,0.0022697959,0.006180427,0.0022281385,0.0060617295,0.005611465],"category_scores_gemma":[0.017070279,0.00037734644,0.0016475313,0.0015022298,0.0034344625,0.009023856,0.0021797172,0.0131901605,0.0020551893],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00068087433,0.00024974882,0.0043784673,0.0040571843,0.0003135252,0.0014279655,0.000530596,0.00048685886,0.00035971872,0.007143158,0.23000054,0.7503714],"study_design_scores_gemma":[0.00034310948,0.0009306443,0.0151051795,0.03921224,0.0008216519,0.0075866343,0.0070584863,0.00097394706,0.00040144488,0.040990315,0.88631094,0.00026538924],"about_ca_topic_score_codex":0.0081810355,"about_ca_topic_score_gemma":0.028995186,"teacher_disagreement_score":0.0081810355,"about_ca_system_score_codex":0.0036041494,"about_ca_system_score_gemma":0.005595436,"threshold_uncertainty_score":0.037065983},"labels":[],"label_agreement":null},{"id":"W4403597409","doi":"10.58931/cht.2022.1s1130","title":"Expert clinical framework report: Management of adverse events related to novel therapies for relapsed/refractory multiple myeloma (RRMM)","year":2022,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Charles-Le Moyne; Saskatchewan Cancer Agency; Saint John Regional Hospital; Capital District Health Authority; Southlake Regional Health Center; Alberta Cancer Foundation","funders":"","keywords":"Medicine; Multiple myeloma; Adverse effect; Lenalidomide; Intensive care medicine; Internal medicine","score_opus":0.04678523042382879,"score_gpt":0.36160123150018186,"score_spread":0.3148160010763531,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403597409","genre_codex":"commentary","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00092211016,0.026185986,0.012569986,0.6290895,0.03515061,0.009049182,0.0077769747,0.0016115564,0.2776442],"genre_scores_gemma":[0.024995513,0.06986794,0.07196694,0.5453662,0.10288777,0.01391203,0.018957945,0.0010889362,0.15095681],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.97956425,0.008876161,0.0030740774,0.0015132091,0.0054279664,0.0015444185],"domain_scores_gemma":[0.93463564,0.0118921315,0.009240194,0.0017169614,0.028993439,0.013521725],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014973134,0.0016135313,0.0017469799,0.0019654573,0.0029430895,0.006094508,0.0049635638,0.016838266,0.083825015],"category_scores_gemma":[0.07509019,0.0005641359,0.00348105,0.0015216395,0.001183579,0.002994403,0.0074647367,0.008770652,0.040213604],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005932429,0.000075423995,0.00039274496,0.001149019,0.000031650095,0.00023717657,0.000069333124,0.0003381994,0.00007450711,0.0018867071,0.8874315,0.10825445],"study_design_scores_gemma":[0.00021813877,0.00011723022,0.0010068788,0.0066678408,0.0000531741,0.000479449,0.0001240369,0.00047552417,0.00009757406,0.0048903306,0.9858285,0.000041327323],"about_ca_topic_score_codex":0.006551209,"about_ca_topic_score_gemma":0.011438336,"teacher_disagreement_score":0.083825015,"about_ca_system_score_codex":0.0060272254,"about_ca_system_score_gemma":0.028691698,"threshold_uncertainty_score":0.28042263},"labels":[],"label_agreement":null},{"id":"W4403597428","doi":"10.58931/cht.2022.1s0628","title":"Safety and tolerability of Bruton's tyrosine kinase inhibitors in the treatment of Waldenström macroglobulinemia","year":2022,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Tolerability; Macroglobulinemia; Waldenstrom macroglobulinemia; Bruton's tyrosine kinase; Medicine; Ibrutinib; Tyrosine kinase; Internal medicine; Cancer research; Oncology; Dermatology; Pharmacology; Adverse effect; Leukemia; Lymphoma; Multiple myeloma; Chronic lymphocytic leukemia","score_opus":0.013813099664741544,"score_gpt":0.27124554376102017,"score_spread":0.25743244409627863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403597428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9545794,0.032587856,0.0012284042,0.0011928747,0.00028117822,0.00045886356,0.0018526801,0.00011656396,0.007702171],"genre_scores_gemma":[0.9905089,0.0051380815,0.00040944322,0.000822979,0.00023772696,0.00022856962,0.0010226738,0.000025477553,0.0016061108],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9992663,0.00030611822,0.000079150515,0.00007168113,0.00019267843,0.00008409674],"domain_scores_gemma":[0.998701,0.00036913453,0.0003899499,0.00007124567,0.00022924675,0.00023947695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001337466,0.00025755123,0.0012665566,0.00019265815,0.0002693777,0.0007569016,0.00031991253,0.0005224887,0.0024286048],"category_scores_gemma":[0.002413098,0.00013882424,0.001047191,0.00034716274,0.00024400682,0.0005128454,0.00021283844,0.001977281,0.0006242451],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23374538,0.011624029,0.03897803,0.0031035536,0.0021087555,0.0016625915,0.0007061439,0.0052070864,0.07676067,0.00072463346,0.0126396585,0.6127394],"study_design_scores_gemma":[0.04238433,0.4330636,0.35406354,0.0012007633,0.004833463,0.0068058013,0.000766396,0.00927276,0.041054808,0.0017467047,0.10453664,0.0002712593],"about_ca_topic_score_codex":0.000722196,"about_ca_topic_score_gemma":0.0011441457,"teacher_disagreement_score":0.0024286048,"about_ca_system_score_codex":0.00057659496,"about_ca_system_score_gemma":0.0005864783,"threshold_uncertainty_score":0.008124471},"labels":[],"label_agreement":null},{"id":"W4403602249","doi":"10.58931/cht.2023.2s1137","title":"An internet-based educational algorithm for the work-up, diagnosis and management of patients with myelodysplastic syndromes from the Canadian Consortium on MDS","year":2023,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; Centre Hospitalier de l’Université de Montréal; Juravinski Cancer Centre; St. Paul's Hospital","funders":"McGill University; Celgene","keywords":"Myelodysplastic syndromes; The Internet; Algorithm; Computer science; Work (physics); Medicine; Engineering; World Wide Web; Internal medicine","score_opus":0.022116641355186827,"score_gpt":0.2811855605360896,"score_spread":0.2590689191809028,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403602249","genre_codex":"other","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.045629963,0.008914223,0.16532819,0.1523981,0.0051085614,0.038987953,0.11819027,0.024788514,0.44065425],"genre_scores_gemma":[0.09272427,0.010173288,0.6852556,0.02520238,0.0014775017,0.013706652,0.079018,0.0015949215,0.09084736],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984761,0.00039452955,0.0002735966,0.00013036423,0.00045959072,0.00026582816],"domain_scores_gemma":[0.9937382,0.0010470686,0.00048828946,0.00014279413,0.0034318473,0.0011518338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002650275,0.001502304,0.0007778028,0.005286256,0.0018917072,0.0020377908,0.0019685745,0.0017416882,0.04965356],"category_scores_gemma":[0.012946296,0.0005774034,0.0012297222,0.0025558006,0.0004631145,0.0018068521,0.0022709926,0.0024756168,0.015124285],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002172004,0.00030580634,0.010489476,0.00039345215,0.000037394868,0.000977584,0.0004003338,0.0021161598,0.00040810806,0.002124428,0.7698291,0.21270104],"study_design_scores_gemma":[0.00087148,0.00029867527,0.04708615,0.0028913629,0.00016765656,0.002519139,0.0009046334,0.011344362,0.0012132088,0.008595541,0.9238202,0.0002876172],"about_ca_topic_score_codex":0.14906183,"about_ca_topic_score_gemma":0.26472336,"teacher_disagreement_score":0.14906183,"about_ca_system_score_codex":0.008955353,"about_ca_system_score_gemma":0.015152757,"threshold_uncertainty_score":0.2963884},"labels":[],"label_agreement":null},{"id":"W4403602456","doi":"10.58931/cht.2023.2339","title":"The role of FDG-PET scanning and PET-adapted therapy in the primary treatment of Hodgkin lymphoma: A primer for clinicians","year":2023,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Primer (cosmetics); Pet imaging; PET-CT; Medicine; Hodgkin lymphoma; Lymphoma; Medical physics; Nuclear medicine; Positron emission tomography; Radiology; Internal medicine; Chemistry","score_opus":0.024063330741172503,"score_gpt":0.2874105923960588,"score_spread":0.2633472616548863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403602456","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007577262,0.77133816,0.007810722,0.20739014,0.0062531317,0.000046084882,0.000038762202,0.00012942094,0.006235936],"genre_scores_gemma":[0.013214128,0.8838865,0.02032626,0.05798142,0.021822909,0.00012412341,0.00007654726,0.000083231556,0.0024849102],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973648,0.0010959565,0.0004263585,0.00023044668,0.00071948586,0.0001629931],"domain_scores_gemma":[0.99027026,0.0055574393,0.00055276486,0.00029130006,0.0024242399,0.0009040927],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010072722,0.0010127776,0.0017764322,0.0027293817,0.0010803893,0.00483831,0.0020754326,0.006008358,0.0017202916],"category_scores_gemma":[0.014566491,0.00062305393,0.0007311713,0.0016842723,0.0055072494,0.008463696,0.0020814668,0.017278869,0.0015082576],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001565101,0.00013214962,0.0031686167,0.0026787866,0.000060004433,0.0027713175,0.0014403508,0.00057014293,0.0017446938,0.023383351,0.19801366,0.76588047],"study_design_scores_gemma":[0.00006122498,0.00021242218,0.002742604,0.008834501,0.00007662134,0.012498206,0.0020236361,0.00077657244,0.00058916246,0.0385297,0.93351084,0.00014443061],"about_ca_topic_score_codex":0.00584774,"about_ca_topic_score_gemma":0.009011217,"teacher_disagreement_score":0.010072722,"about_ca_system_score_codex":0.003883613,"about_ca_system_score_gemma":0.004532763,"threshold_uncertainty_score":0.05327028},"labels":[],"label_agreement":null},{"id":"W4403602474","doi":"10.58931/cht.2023.2338","title":"Bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapy for indolent lymphoma","year":2023,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Chimeric antigen receptor; Lymphoma; Antibody; Bispecific antibody; Antigen; Medicine; Virology; Immunology; Antibody therapy; Cancer research; Immunotherapy; Monoclonal antibody; Immune system","score_opus":0.0350963459906627,"score_gpt":0.3005168672949186,"score_spread":0.2654205213042559,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403602474","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4700958,0.4091318,0.014030732,0.007591908,0.0012462328,0.00052101025,0.00068496214,0.00079910515,0.0958985],"genre_scores_gemma":[0.84881157,0.11691049,0.006458211,0.0027003419,0.00047619204,0.00020505037,0.00095834315,0.000043289667,0.02343657],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99992406,0.000017079816,0.00000359465,0.000007287394,0.000025828766,0.000022141427],"domain_scores_gemma":[0.9999608,0.000008295891,0.000008265008,0.0000024220828,0.000006512998,0.000013706876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021568089,0.00018695682,0.00020283546,0.00046182965,0.00013876124,0.00021456507,0.0002560882,0.00034032145,0.002848529],"category_scores_gemma":[0.00015966267,0.000044359473,0.00016421583,0.00029302706,0.00020928479,0.00019765655,0.0001967996,0.00054003345,0.0007626452],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023137135,0.0012377191,0.0027532806,0.00063773355,0.000080087826,0.0011474744,0.00009421258,0.0017888452,0.0582488,0.008206646,0.0195932,0.9038985],"study_design_scores_gemma":[0.0033976806,0.016138393,0.036707398,0.0003760683,0.00031647156,0.010291294,0.00014029573,0.004264766,0.074708514,0.0059197713,0.84767914,0.00006034113],"about_ca_topic_score_codex":0.0033148525,"about_ca_topic_score_gemma":0.0068392097,"teacher_disagreement_score":0.0033148525,"about_ca_system_score_codex":0.0006546823,"about_ca_system_score_gemma":0.0005578128,"threshold_uncertainty_score":0.009529293},"labels":[],"label_agreement":null},{"id":"W4403622122","doi":"10.58931/cht.2024.3146","title":"Front-line Management of Follicular Lymphoma","year":2024,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Front line; Follicular lymphoma; Line (geometry); Front (military); Lymphoma; Medicine; Computer science; Geology; Internal medicine; History; Mathematics; Oceanography; Geometry","score_opus":0.012860254862607789,"score_gpt":0.25845115870483865,"score_spread":0.24559090384223087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403622122","genre_codex":"other","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3095126,0.22826271,0.02663436,0.024276653,0.0024495693,0.0010918521,0.004000811,0.002579719,0.40119183],"genre_scores_gemma":[0.86464477,0.047007315,0.011415655,0.012183569,0.0016453505,0.00028071823,0.005874183,0.00023595941,0.05671243],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99981743,0.000014868186,0.000009208091,0.000018472021,0.00007458237,0.00006541203],"domain_scores_gemma":[0.9997888,0.000012022518,0.000021263579,0.000009837548,0.000070478076,0.0000977058],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017687782,0.00026449168,0.0003432316,0.0005420677,0.0008083628,0.000702408,0.00064448826,0.0005092077,0.008231371],"category_scores_gemma":[0.00044320873,0.00007028503,0.00036463683,0.00029042433,0.00017365538,0.00036298676,0.0004304621,0.0008505098,0.0032022307],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00087862986,0.00043794597,0.01955882,0.000662588,0.00011269405,0.010378334,0.00026564614,0.00078241737,0.010749297,0.0016513753,0.14551443,0.8090078],"study_design_scores_gemma":[0.00056170736,0.0015590562,0.075244926,0.0018645319,0.0003027255,0.0719195,0.00065343454,0.0029969655,0.010522747,0.004233416,0.83008057,0.00006057594],"about_ca_topic_score_codex":0.014718398,"about_ca_topic_score_gemma":0.03175918,"teacher_disagreement_score":0.014718398,"about_ca_system_score_codex":0.001945404,"about_ca_system_score_gemma":0.001063482,"threshold_uncertainty_score":0.029265463},"labels":[],"label_agreement":null},{"id":"W4403622129","doi":"10.58931/cht.2024.3255","title":"Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia After BTK Inhibitor and/or BCL-2 Inhibitor Failure","year":2024,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Chronic lymphocytic leukemia; Refractory (planetary science); Bruton's tyrosine kinase; Ibrutinib; Medicine; Internal medicine; Cancer research; Leukemia; Biology; Receptor","score_opus":0.01358765583586513,"score_gpt":0.2729650758220165,"score_spread":0.2593774199861514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403622129","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.49672744,0.38058722,0.0145637235,0.014048211,0.0026293832,0.0007945894,0.0013962938,0.0013900744,0.08786308],"genre_scores_gemma":[0.90882605,0.06127083,0.004049057,0.007997942,0.0014018813,0.00031043228,0.0020157443,0.00011298112,0.014014997],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99986374,0.00003790229,0.0000123444115,0.000015506575,0.000024858826,0.00004551481],"domain_scores_gemma":[0.99985886,0.000033204844,0.000028872151,0.000009094336,0.000017986877,0.00005198807],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035184406,0.00025270783,0.00053148484,0.00044911396,0.00034708713,0.00047510286,0.00030911187,0.00045175443,0.002590686],"category_scores_gemma":[0.0005209655,0.00006538459,0.00043426148,0.00025788494,0.00022250545,0.00032979882,0.00038719122,0.0008344074,0.0010883476],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004994039,0.0007076818,0.014461934,0.0014996578,0.0002853281,0.014057702,0.00043090145,0.0017165218,0.018887505,0.0030532726,0.054781932,0.88512355],"study_design_scores_gemma":[0.003971424,0.0151342405,0.073126145,0.0038374686,0.0005237897,0.08092078,0.00063207914,0.005564231,0.02334429,0.013310822,0.7794943,0.00014050203],"about_ca_topic_score_codex":0.00053933077,"about_ca_topic_score_gemma":0.0020789653,"teacher_disagreement_score":0.002590686,"about_ca_system_score_codex":0.00059294136,"about_ca_system_score_gemma":0.00037433804,"threshold_uncertainty_score":0.008666694},"labels":[],"label_agreement":null},{"id":"W4403622133","doi":"10.58931/cht.2024.3254","title":"High-Risk Myeloma: Definitions and Treatments","year":2024,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Multiple myeloma; Medicine; Internal medicine","score_opus":0.028396329164918483,"score_gpt":0.2820652679824287,"score_spread":0.25366893881751024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403622133","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015191846,0.7889432,0.017028466,0.08842569,0.005436148,0.0010971805,0.0025433449,0.00023105677,0.08110311],"genre_scores_gemma":[0.1503643,0.7229906,0.049913988,0.033278484,0.015691267,0.0021098051,0.009860108,0.00023307388,0.015558411],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979411,0.00057948084,0.00046064515,0.0002429662,0.0005301402,0.00024567058],"domain_scores_gemma":[0.9980515,0.00021078532,0.0004859535,0.00006871397,0.00065196975,0.00053107535],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029954023,0.0009831678,0.0012338032,0.0037111735,0.0015934395,0.0025101595,0.0020336187,0.0015905275,0.0029028943],"category_scores_gemma":[0.004313123,0.00029971148,0.0009315286,0.0051556276,0.002206807,0.0020774414,0.003531373,0.0041009868,0.0014070589],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047185406,0.00049441535,0.030391308,0.004265837,0.00013926234,0.0013113772,0.0015801267,0.001953311,0.0013342692,0.16517879,0.28450888,0.5083705],"study_design_scores_gemma":[0.000085887266,0.00018963806,0.023689482,0.0066248863,0.00011495112,0.007843881,0.0011713927,0.0007880703,0.00036127729,0.05566782,0.90337086,0.0000919253],"about_ca_topic_score_codex":0.009200086,"about_ca_topic_score_gemma":0.008867993,"teacher_disagreement_score":0.009200086,"about_ca_system_score_codex":0.0052498966,"about_ca_system_score_gemma":0.007215955,"threshold_uncertainty_score":0.038090885},"labels":[],"label_agreement":null},{"id":"W4403622134","doi":"10.58931/cht.2023.2341","title":"Frontline treatment of aggressive B-cell lymphoma","year":2023,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Lymphoma; Aggressive lymphoma; B-cell lymphoma; Medicine; Cancer research; Internal medicine; Rituximab","score_opus":0.01861575547947897,"score_gpt":0.2644674569887634,"score_spread":0.24585170150928443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403622134","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05753309,0.48066038,0.019030478,0.018103486,0.009415156,0.0007582056,0.007344045,0.0025060726,0.40464908],"genre_scores_gemma":[0.3764472,0.3203306,0.020107849,0.024076542,0.010568399,0.0008094823,0.026755052,0.00060511497,0.22029983],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998778,0.000019726534,0.000008458859,0.000014902004,0.000048709328,0.000030333913],"domain_scores_gemma":[0.9998764,0.00001773126,0.000020150175,0.0000066811313,0.000033984474,0.000045040662],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014018772,0.00032138568,0.000442458,0.00055097224,0.0002374466,0.0005317828,0.00045746416,0.00048355813,0.024863476],"category_scores_gemma":[0.0003185354,0.000055056924,0.00041943134,0.00033549804,0.00010538716,0.00039292662,0.0002835412,0.0010037697,0.014458733],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006678686,0.00023496366,0.0013269606,0.001156214,0.00011880938,0.0011700864,0.000048204358,0.00044699223,0.0051001594,0.0016343817,0.21842766,0.7696676],"study_design_scores_gemma":[0.00032797555,0.00043586074,0.0059830747,0.0008711335,0.00010254496,0.0043732636,0.00004459665,0.00038592846,0.0026681342,0.0019571162,0.9828342,0.000016223668],"about_ca_topic_score_codex":0.0009711476,"about_ca_topic_score_gemma":0.0028401506,"teacher_disagreement_score":0.024863476,"about_ca_system_score_codex":0.0005592776,"about_ca_system_score_gemma":0.0002885118,"threshold_uncertainty_score":0.08317661},"labels":[],"label_agreement":null},{"id":"W4403622135","doi":"10.58931/cht.2024.3148","title":"Follicular Non-Hodgkin Lymphoma: First Relapse and Beyond","year":2024,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Nova Scotia Health Authority","funders":"Acadia University","keywords":"Follicular lymphoma; Follicular phase; Lymphoma; Medicine; Oncology; Hodgkin lymphoma; Internal medicine","score_opus":0.007170227836454627,"score_gpt":0.2335209303813079,"score_spread":0.22635070254485326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403622135","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004534261,0.96519387,0.00030376393,0.0050861407,0.00054592476,0.00005390299,0.00041495485,0.000043793327,0.023823412],"genre_scores_gemma":[0.06910704,0.9133821,0.0010460711,0.005555557,0.0009681369,0.000039429175,0.0008822758,0.000021061565,0.008998432],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99960583,0.0000510349,0.000036633595,0.00003788189,0.00017996077,0.00008873176],"domain_scores_gemma":[0.99923587,0.00014293448,0.0001131952,0.000022959526,0.00037579145,0.00010926335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006792998,0.0003002629,0.00093221397,0.00081812614,0.0005244421,0.0011859337,0.00065178925,0.00075698266,0.004913237],"category_scores_gemma":[0.0015221772,0.000117869284,0.00059562473,0.0011559674,0.00053655094,0.00070657156,0.00044435178,0.0010624354,0.00086249976],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039826785,0.00006413453,0.0049645966,0.012951271,0.00013166167,0.001985528,0.00046618906,0.00025318767,0.0016502448,0.0074649174,0.098322414,0.87134767],"study_design_scores_gemma":[0.0000915786,0.00014818815,0.010510639,0.009067825,0.00029766528,0.008797337,0.00040501147,0.00012890068,0.0007808099,0.002775784,0.96695495,0.00004112651],"about_ca_topic_score_codex":0.14215998,"about_ca_topic_score_gemma":0.2715472,"teacher_disagreement_score":0.14215998,"about_ca_system_score_codex":0.005025566,"about_ca_system_score_gemma":0.008641175,"threshold_uncertainty_score":0.28266507},"labels":[],"label_agreement":null},{"id":"W4403622138","doi":"10.58931/cht.2024.3149","title":"Systemic Mastocytosis: Diagnosis and Management in 2024","year":2024,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Mast cells and histamine","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital","funders":"University of Toronto","keywords":"Systemic mastocytosis; Medicine; Dermatology; Intensive care medicine; Pathology; Bone marrow","score_opus":0.009494273569585645,"score_gpt":0.21626526331138224,"score_spread":0.20677098974179658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403622138","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.107426904,0.76144195,0.011131274,0.035797402,0.0030934259,0.00024973383,0.0004839716,0.00023365626,0.080141686],"genre_scores_gemma":[0.537763,0.4147281,0.012025149,0.014174061,0.007575566,0.00010470908,0.001132235,0.0000451365,0.012452032],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99981815,0.000026126918,0.000026488142,0.000019569949,0.00006469034,0.00004499125],"domain_scores_gemma":[0.999846,0.000024942447,0.00002840888,0.0000034752675,0.000039631217,0.000057492805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002688135,0.00040060916,0.00046224013,0.0007436596,0.0005731548,0.00064188696,0.00040415386,0.0010328926,0.0015625055],"category_scores_gemma":[0.00074679864,0.00014887794,0.00018810332,0.0006229803,0.00032546933,0.0005404769,0.0005571943,0.00112686,0.0005812232],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030975332,0.00017917284,0.06706282,0.0014312172,0.00006978558,0.30967265,0.0012826925,0.00074365264,0.008706377,0.006232097,0.08430579,0.5200041],"study_design_scores_gemma":[0.000054041317,0.00022087274,0.036217462,0.0031987564,0.0000768586,0.7115925,0.0015427638,0.00083822286,0.0012161633,0.0049765757,0.24001105,0.000054777553],"about_ca_topic_score_codex":0.0058365203,"about_ca_topic_score_gemma":0.008524476,"teacher_disagreement_score":0.0058365203,"about_ca_system_score_codex":0.0008858514,"about_ca_system_score_gemma":0.001354528,"threshold_uncertainty_score":0.011605084},"labels":[],"label_agreement":null},{"id":"W4403622146","doi":"10.58931/cht.2024.3253","title":"Management of Chronic Myeloid Leukemia that is Intolerant or Resistant to Front-Line Treatment","year":2024,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Myeloid leukemia; Front line; Medicine; Front (military); Line (geometry); Myeloid; Cancer research; Oncology; Internal medicine; History; Engineering; Mathematics","score_opus":0.026433980741656118,"score_gpt":0.28653558425074394,"score_spread":0.26010160350908784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403622146","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4790186,0.2818383,0.022071533,0.0647699,0.002836209,0.001632012,0.0009706196,0.00071809284,0.14614473],"genre_scores_gemma":[0.85207295,0.07693257,0.01743546,0.029550316,0.0066818153,0.0005063087,0.0015839441,0.00009847757,0.015138119],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99978274,0.000044473483,0.000027430142,0.000025908197,0.00006112491,0.000058321802],"domain_scores_gemma":[0.99973184,0.000040443225,0.00007235228,0.000006719806,0.00003746056,0.000111175774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032749906,0.00031007556,0.0006186038,0.00043348232,0.0006246375,0.00081864203,0.00042284976,0.00075497024,0.0028301603],"category_scores_gemma":[0.00093937136,0.00007355928,0.0003005728,0.00032558013,0.00027789897,0.00050258817,0.0006718939,0.001087863,0.0008987328],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014129903,0.00063696963,0.06251633,0.0025735055,0.00014509437,0.0750084,0.0011111797,0.0019201552,0.01749113,0.008599205,0.108010314,0.7205746],"study_design_scores_gemma":[0.00067515176,0.0038811658,0.07054605,0.0045098797,0.00028559804,0.30155125,0.0022249771,0.0050858324,0.0064861495,0.015648222,0.5890161,0.00008961254],"about_ca_topic_score_codex":0.00040878088,"about_ca_topic_score_gemma":0.0011640447,"teacher_disagreement_score":0.0028301603,"about_ca_system_score_codex":0.0006002686,"about_ca_system_score_gemma":0.0006390769,"threshold_uncertainty_score":0.009467781},"labels":[],"label_agreement":null},{"id":"W4403622155","doi":"10.58931/cht.2024.3251","title":"Mantle Cell Lymphoma: Evolving Frontline Treatment Strategies","year":2024,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"University of Toronto","keywords":"Mantle cell lymphoma; Mantle (geology); Geology; Lymphoma; Earth science; Geochemistry; Medicine; Internal medicine","score_opus":0.012498502379326561,"score_gpt":0.25695230629642807,"score_spread":0.2444538039171015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403622155","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008691819,0.94280964,0.0057851626,0.028775327,0.0021201796,0.00013868157,0.00025358377,0.00022137363,0.011204246],"genre_scores_gemma":[0.06657576,0.8687378,0.018644532,0.0284488,0.008711083,0.00034278416,0.0019309074,0.00010048684,0.006507823],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99945754,0.00014149716,0.0000650909,0.00010411292,0.00013617089,0.000095638665],"domain_scores_gemma":[0.99906284,0.00023393748,0.00011320301,0.000037778536,0.00029935726,0.00025275885],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020527109,0.00066931924,0.0011164789,0.0009929152,0.0003381148,0.0016453884,0.001338896,0.0009527974,0.004792578],"category_scores_gemma":[0.001662049,0.00018579177,0.0008157534,0.0005319932,0.00051144557,0.0019979484,0.0012057073,0.0035656656,0.0017266736],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039653436,0.00028890307,0.0015128478,0.0016340656,0.00011078172,0.00024925487,0.00006843091,0.0010686567,0.0014676622,0.00524565,0.031999335,0.9559579],"study_design_scores_gemma":[0.0006530535,0.0019872629,0.004918769,0.009657269,0.00054989423,0.003175669,0.0003744935,0.0034775038,0.0018409131,0.016098306,0.95719016,0.00007671034],"about_ca_topic_score_codex":0.00083458,"about_ca_topic_score_gemma":0.0033067695,"teacher_disagreement_score":0.004792578,"about_ca_system_score_codex":0.0013732055,"about_ca_system_score_gemma":0.0012986585,"threshold_uncertainty_score":0.016032755},"labels":[],"label_agreement":null},{"id":"W4403622159","doi":"10.58931/cht.2024.3150","title":"Maintenance Therapy for CD20+ Indolent Lymphoma: Who Should Receive Maintenance?","year":2024,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa","funders":"","keywords":"Maintenance therapy; Medicine; Lymphoma; CD20; Oncology; Intensive care medicine; Internal medicine; Medical physics; Chemotherapy","score_opus":0.02888856460784047,"score_gpt":0.2892735946245331,"score_spread":0.26038503001669266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403622159","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015592966,0.9726901,0.00012941677,0.022389594,0.0005938298,0.00001591326,0.00008832285,0.0000065066306,0.0025270125],"genre_scores_gemma":[0.037584342,0.93395495,0.0011637136,0.022025133,0.003080821,0.000064626925,0.00029238863,0.000014288267,0.0018197442],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99931026,0.00020309023,0.0001340584,0.00009007752,0.00018431415,0.000078240264],"domain_scores_gemma":[0.996906,0.0015188688,0.0004458109,0.00006860559,0.00082098576,0.00023986245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025691458,0.00019577882,0.0015428131,0.00044566212,0.00043304698,0.0014264114,0.0010339697,0.0013727994,0.0038764183],"category_scores_gemma":[0.0063871467,0.00012834014,0.0005717744,0.00079647335,0.0007480148,0.0015155915,0.0003138234,0.0021906735,0.0007470798],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011089313,0.00006333133,0.00224356,0.013718721,0.0002801428,0.00015553088,0.00026588122,0.00013268582,0.00070575543,0.00344491,0.06342379,0.91445684],"study_design_scores_gemma":[0.00089928054,0.00047785853,0.010379104,0.042474836,0.0011630105,0.0008265758,0.00056215434,0.0001626739,0.00041509545,0.0041786763,0.9384063,0.000054484983],"about_ca_topic_score_codex":0.028858127,"about_ca_topic_score_gemma":0.090587966,"teacher_disagreement_score":0.028858127,"about_ca_system_score_codex":0.0028891414,"about_ca_system_score_gemma":0.0052402904,"threshold_uncertainty_score":0.05738032},"labels":[],"label_agreement":null},{"id":"W4403622162","doi":"10.58931/cht.2023.2342","title":"Chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma: The evolving Canadian landscape","year":2023,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Gilead Sciences; Sanofi","keywords":"Chimeric antigen receptor; Multiple myeloma; Antigen; Immunology; Receptor; Medicine; Cancer research; Virology; Biology; Immunotherapy; Internal medicine; Immune system","score_opus":0.027811339048661968,"score_gpt":0.2724164986273658,"score_spread":0.24460515957870382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403622162","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0054283896,0.71270007,0.0016145967,0.2474798,0.0034936992,0.000047762696,0.00034440294,0.00012443193,0.028766925],"genre_scores_gemma":[0.062792145,0.8873407,0.002804045,0.03378167,0.003504518,0.00006161958,0.00038404114,0.000086939806,0.00924418],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99797815,0.00037802372,0.000120168756,0.00023342934,0.0009601635,0.00033000854],"domain_scores_gemma":[0.9927597,0.0012672015,0.00037403766,0.00010568454,0.0040381243,0.0014552783],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006274331,0.0004954903,0.00077448343,0.0020908315,0.0022206127,0.0030554147,0.0015865618,0.0022050869,0.010979028],"category_scores_gemma":[0.006724352,0.00021285935,0.00044723868,0.0041116513,0.0034961714,0.002300664,0.0018457253,0.0040402855,0.00163429],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00061293907,0.00022410939,0.0025084668,0.0021591817,0.00009710116,0.000458862,0.0003851192,0.0012363314,0.001964833,0.055516142,0.18883394,0.7460031],"study_design_scores_gemma":[0.00016745873,0.00028360807,0.0030861103,0.001484023,0.00011261694,0.0006127977,0.00048267937,0.00060020026,0.00075278495,0.006602238,0.9857686,0.00004695047],"about_ca_topic_score_codex":0.42789638,"about_ca_topic_score_gemma":0.6190782,"teacher_disagreement_score":0.5721036,"about_ca_system_score_codex":0.02738625,"about_ca_system_score_gemma":0.049244344,"threshold_uncertainty_score":0.8508115},"labels":[],"label_agreement":null},{"id":"W4403622166","doi":"10.58931/cht.2024.3252","title":"Therapy for Myelodysplastic Syndromes Beyond the Front Line in 2024 in Canada","year":2024,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Sunnybrook Research Institute; Leukemia and Lymphoma Society of Canada","keywords":"Front line; Myelodysplastic syndromes; Medicine; History; Internal medicine; Archaeology","score_opus":0.018813981114614547,"score_gpt":0.2800930793534141,"score_spread":0.2612790982387996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403622166","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0433624,0.65485114,0.0018199998,0.11539627,0.005681631,0.0004277538,0.01494442,0.00027480497,0.16324157],"genre_scores_gemma":[0.2289228,0.63827014,0.007632174,0.034393698,0.0015223998,0.00022625875,0.015340007,0.00012406768,0.0735685],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99953556,0.00004578878,0.00003396573,0.000034585144,0.00021128144,0.0001388423],"domain_scores_gemma":[0.9986903,0.000062734995,0.00009774794,0.000013175112,0.000642409,0.00049365463],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007115317,0.0003004788,0.0003748004,0.00081842946,0.0011993815,0.0011919024,0.0007590143,0.00068455876,0.012487958],"category_scores_gemma":[0.0013785543,0.00014623663,0.00047544605,0.0016047705,0.00038650917,0.00039192464,0.0005762453,0.0014164008,0.0011845896],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008305878,0.00015130125,0.010674786,0.0031331934,0.00015972521,0.0016454895,0.00044700768,0.0009468669,0.0029705996,0.014487001,0.3906224,0.57393104],"study_design_scores_gemma":[0.00027726815,0.00015927607,0.021001779,0.0022608761,0.0001543268,0.0010222655,0.00025710845,0.00027737342,0.00062739383,0.0009637439,0.9729633,0.000035369154],"about_ca_topic_score_codex":0.9100958,"about_ca_topic_score_gemma":0.9712414,"teacher_disagreement_score":0.08990419,"about_ca_system_score_codex":0.025911614,"about_ca_system_score_gemma":0.08620136,"threshold_uncertainty_score":0.18800282},"labels":[],"label_agreement":null},{"id":"W4403622168","doi":"10.58931/cht.2024.3s01-244","title":"Navigating the Paradigm Shift in Chronic Lymphocytic Leukemia Treatment from Chemotherapy to Targeted Therapies","year":2024,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University","funders":"","keywords":"Paradigm shift; Chronic lymphocytic leukemia; Chemotherapy; Medicine; Oncology; Leukemia; Intensive care medicine; Internal medicine; Philosophy","score_opus":0.018349464783164363,"score_gpt":0.312699512954759,"score_spread":0.29435004817159466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403622168","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019860896,0.6621487,0.0024920364,0.3017982,0.004747471,0.000073609015,0.00016094377,0.000069347254,0.02652353],"genre_scores_gemma":[0.032794926,0.8810926,0.0069766687,0.0698892,0.0033556519,0.000076229866,0.00024547885,0.00006369044,0.0055054333],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99254566,0.0023783364,0.0005277718,0.00036198506,0.0031477327,0.0010384883],"domain_scores_gemma":[0.99093086,0.0018911305,0.00047395998,0.00016289827,0.005184515,0.0013567021],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010735745,0.00043333255,0.0012160214,0.0018926412,0.0031790033,0.0061258464,0.0025110524,0.0023441392,0.004190291],"category_scores_gemma":[0.010072232,0.0002534766,0.0006638875,0.002939486,0.005294419,0.0027796375,0.0027200696,0.006855345,0.001073541],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022535757,0.00008748008,0.002085209,0.009074621,0.00013725442,0.0012882901,0.00487339,0.0012592244,0.0028097339,0.10538798,0.29391283,0.5788587],"study_design_scores_gemma":[0.00003141835,0.000042696487,0.0008715363,0.002617604,0.000034029177,0.00035726564,0.0011555994,0.000089276546,0.0002904726,0.0071728136,0.98730195,0.00003529638],"about_ca_topic_score_codex":0.57392544,"about_ca_topic_score_gemma":0.8113444,"teacher_disagreement_score":0.57392544,"about_ca_system_score_codex":0.03931568,"about_ca_system_score_gemma":0.12962128,"threshold_uncertainty_score":0.8571676},"labels":[],"label_agreement":null},{"id":"W4403622172","doi":"10.58931/cht.2023.2340","title":"Monoclonal gammopathy of clinical and undetermined significance","year":2023,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Monoclonal gammopathy of undetermined significance; Monoclonal gammopathy; Paraproteinemias; Medicine; Monoclonal; Immunology; Monoclonal antibody; Antibody","score_opus":0.07689407381640198,"score_gpt":0.3801003601665178,"score_spread":0.3032062863501158,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403622172","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.62104625,0.0570719,0.002761295,0.006345575,0.0008628475,0.00081387383,0.004605383,0.00042523834,0.3060676],"genre_scores_gemma":[0.9678248,0.0074129654,0.0013390613,0.0012620771,0.00034860714,0.000058383466,0.0019385738,0.00001824659,0.019797156],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99971443,0.000036067537,0.000028481854,0.000031975982,0.00010978802,0.00007921781],"domain_scores_gemma":[0.9995733,0.000050201998,0.00009809755,0.000020116768,0.00014860864,0.00010978844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031665902,0.00034739266,0.0004101463,0.0014168527,0.00059864536,0.0004791698,0.00032471653,0.0006564958,0.0068673054],"category_scores_gemma":[0.0013108798,0.000072088886,0.00023084146,0.0010750956,0.00033091815,0.00029717118,0.00028731034,0.00037449275,0.0012364468],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012739005,0.00035501,0.6204309,0.0010421405,0.00014565261,0.09005702,0.00058154017,0.00022028195,0.02145666,0.006153546,0.053790938,0.20449239],"study_design_scores_gemma":[0.00011876639,0.00047930682,0.6617682,0.00080540543,0.00018749101,0.17794327,0.00035017577,0.000526946,0.0042226114,0.0020532394,0.15149651,0.00004802528],"about_ca_topic_score_codex":0.00728994,"about_ca_topic_score_gemma":0.010346491,"teacher_disagreement_score":0.00728994,"about_ca_system_score_codex":0.00040799973,"about_ca_system_score_gemma":0.0007513916,"threshold_uncertainty_score":0.022973478},"labels":[],"label_agreement":null},{"id":"W4406091184","doi":"10.58931/cht.2024.3358","title":"Front-line Treatment of Older Patients with Hodgkin Lymphoma","year":2024,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Front line; Hodgkin lymphoma; Medicine; Lymphoma; Oncology; Internal medicine; History; Archaeology","score_opus":0.009216902251404107,"score_gpt":0.23852874471188265,"score_spread":0.22931184246047853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406091184","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9429866,0.03903548,0.0006313129,0.002830673,0.0004369912,0.00012788731,0.00070041325,0.00004609215,0.013204597],"genre_scores_gemma":[0.9806425,0.011488868,0.00060460204,0.0037786386,0.0004753004,0.000058419053,0.0009547761,0.000007739647,0.0019892012],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99989474,0.000026179005,0.000013038515,0.0000109327,0.00002449132,0.00003067848],"domain_scores_gemma":[0.999703,0.000035463894,0.00007678881,0.000010855081,0.000045532543,0.00012834897],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025795796,0.000109240544,0.00029123036,0.00018398656,0.00025662372,0.00026029264,0.00012147769,0.00018539591,0.0014825001],"category_scores_gemma":[0.00079118385,0.000060461185,0.00022753834,0.00020070771,0.00007330634,0.00028755507,0.00025143096,0.00040171627,0.00040361524],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00700421,0.00088412873,0.34944102,0.00091908936,0.0003012489,0.0027394374,0.0008059686,0.0005198526,0.009214353,0.0004731579,0.022752117,0.6049454],"study_design_scores_gemma":[0.0010642946,0.007290911,0.87755436,0.0009886816,0.0005882724,0.00858292,0.00071275653,0.0010398717,0.0019192195,0.0012828584,0.09894017,0.000035664245],"about_ca_topic_score_codex":0.0010649048,"about_ca_topic_score_gemma":0.004148678,"teacher_disagreement_score":0.0014825001,"about_ca_system_score_codex":0.00038438936,"about_ca_system_score_gemma":0.00024742508,"threshold_uncertainty_score":0.0049594045},"labels":[],"label_agreement":null},{"id":"W4406091198","doi":"10.58931/cht.2024.3359","title":"The Evolving Landscape of DLBCL Treatment Beyond the First Line in 2024","year":2024,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Line (geometry); Environmental planning; Geography","score_opus":0.018070650475495022,"score_gpt":0.29264030940429214,"score_spread":0.27456965892879714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406091198","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.021790087,0.5661337,0.004602032,0.32206318,0.0070600403,0.00009810105,0.0008789798,0.00028365888,0.07709025],"genre_scores_gemma":[0.1840651,0.57591087,0.012702838,0.17691007,0.015842041,0.00021273189,0.0031896683,0.00030359684,0.03086309],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988109,0.00031521742,0.00012355634,0.00013478062,0.00036425944,0.0002513391],"domain_scores_gemma":[0.99758756,0.00044501008,0.00025003447,0.00007621665,0.0007352498,0.00090582663],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033906323,0.00036356234,0.0005936204,0.0007825229,0.0009014502,0.003204923,0.0010271221,0.0017480912,0.0096747475],"category_scores_gemma":[0.0030576496,0.00019935376,0.0005743259,0.0008068602,0.0011314852,0.002368509,0.0015749787,0.0033998373,0.002335456],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052656117,0.00015608508,0.002390664,0.0013216775,0.0000550412,0.00059578323,0.0002205258,0.0009124168,0.0034445906,0.02905358,0.124242224,0.83708084],"study_design_scores_gemma":[0.000088565146,0.00039089296,0.002616049,0.0011423626,0.000039219707,0.0013197998,0.00022964492,0.00044284176,0.0009482168,0.006640141,0.98611706,0.000025216834],"about_ca_topic_score_codex":0.009198543,"about_ca_topic_score_gemma":0.026792591,"teacher_disagreement_score":0.0096747475,"about_ca_system_score_codex":0.007645697,"about_ca_system_score_gemma":0.0070643877,"threshold_uncertainty_score":0.055473685},"labels":[],"label_agreement":null},{"id":"W4406091233","doi":"10.58931/cht.2024.3357","title":"Treatment of Philadelphia Chromosome-negative Myeloproliferative Neoplasms in 2024: A Concise Review","year":2024,"lang":"en","type":"review","venue":"Canadian Hematology Today","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Philadelphia chromosome; Genetics; Chromosome; Genealogy; Biology; Medicine; History; Chromosomal translocation; Gene","score_opus":0.05218010246034125,"score_gpt":0.3594279745392955,"score_spread":0.3072478720789542,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406091233","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005486013,0.9990637,0.00005213343,0.00019482593,0.00021296713,0.0000031419736,0.0000149232355,0.0000035556977,0.00040000762],"genre_scores_gemma":[0.00035519738,0.9988752,0.00009961124,0.00022400799,0.00021684036,0.0000041831368,0.00003269441,0.0000010678891,0.00019121173],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99984,0.0000271571,0.00003185699,0.000030704166,0.00005689119,0.000013436369],"domain_scores_gemma":[0.9996505,0.00015941812,0.000063350795,0.0000071883787,0.0000937077,0.000025817757],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041939656,0.0007697681,0.0010512933,0.0020413809,0.00025864557,0.00071372534,0.00071654405,0.0007751184,0.003532536],"category_scores_gemma":[0.0010577565,0.00020487716,0.00047881753,0.0019109852,0.00025100054,0.0010044078,0.00045629524,0.0012993335,0.0013291561],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000066315915,0.000049781996,0.0001482688,0.024591355,0.00010175789,0.00026047658,0.000062688465,0.0003284113,0.00065311394,0.0016725656,0.057995692,0.91406953],"study_design_scores_gemma":[0.000021669166,0.00009807385,0.00080579624,0.013333624,0.0002610964,0.0029807983,0.0000553188,0.00008965189,0.00022134696,0.0010437896,0.98106617,0.000022702941],"about_ca_topic_score_codex":0.0013130553,"about_ca_topic_score_gemma":0.0029318347,"teacher_disagreement_score":0.003532536,"about_ca_system_score_codex":0.0005590799,"about_ca_system_score_gemma":0.0009836864,"threshold_uncertainty_score":0.011817515},"labels":[],"label_agreement":null},{"id":"W4406091238","doi":"10.58931/cht.2024.3360","title":"Minimal Residual Disease in Myeloma in 2024: Where We are Today","year":2024,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Capital District Health Authority","funders":"","keywords":"Minimal residual disease; Multiple myeloma; Residual; Disease; Medicine; Computer science; Internal medicine; Algorithm; Bone marrow","score_opus":0.02206489221781091,"score_gpt":0.29813870958593974,"score_spread":0.27607381736812886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406091238","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.021708418,0.7424003,0.0036499691,0.16023019,0.011079409,0.00012718975,0.00091641274,0.00036837216,0.059519846],"genre_scores_gemma":[0.3175826,0.49367446,0.012481894,0.0926418,0.023860825,0.00016978823,0.0027391745,0.00027695723,0.056572564],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991393,0.00016907934,0.00009706567,0.0000977216,0.00032099147,0.00017582493],"domain_scores_gemma":[0.99879044,0.0001495061,0.00023942965,0.00006020831,0.0004020172,0.0003584348],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001656231,0.00035155856,0.00089912897,0.0012021043,0.001512077,0.003137182,0.00092710793,0.0019289945,0.0055885683],"category_scores_gemma":[0.003060091,0.00020667021,0.00035134482,0.0016460646,0.0015810851,0.0024361878,0.0017968256,0.0035171844,0.002148705],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00066926994,0.00011239498,0.028906332,0.0021213505,0.00008059025,0.00478697,0.0015061892,0.00018613174,0.004445975,0.029013457,0.3109005,0.6172709],"study_design_scores_gemma":[0.00004420759,0.00015458436,0.026646964,0.0021677935,0.00008664841,0.014983738,0.0013626581,0.00013165805,0.0009876095,0.011843711,0.9415237,0.00006670444],"about_ca_topic_score_codex":0.02958282,"about_ca_topic_score_gemma":0.045986906,"teacher_disagreement_score":0.02958282,"about_ca_system_score_codex":0.003443943,"about_ca_system_score_gemma":0.005515179,"threshold_uncertainty_score":0.05882126},"labels":[],"label_agreement":null},{"id":"W4406091245","doi":"10.58931/cht.2024.3356","title":"Relapsed or Refractory Mantle Cell Lymphoma: Available and Emerging Therapies","year":2024,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Mantle cell lymphoma; Refractory (planetary science); Mantle (geology); Medicine; Cancer research; Lymphoma; Oncology; Geology; Internal medicine; Geochemistry; Astrobiology; Biology","score_opus":0.015324093857137127,"score_gpt":0.24940447350731826,"score_spread":0.23408037965018114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406091245","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0050247093,0.9875739,0.0004458717,0.004056206,0.00035154657,0.000014695668,0.000058844653,0.00004548056,0.0024287824],"genre_scores_gemma":[0.045542583,0.9414241,0.0018569956,0.0065501635,0.0024098842,0.000053858104,0.0004132529,0.000027014927,0.00172221],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996594,0.00007910165,0.00004341806,0.00006788421,0.00008828383,0.00006196285],"domain_scores_gemma":[0.999556,0.00016796403,0.000073283845,0.000019943149,0.00008800974,0.00009470447],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010953946,0.00042285564,0.0011750618,0.00076087617,0.00025497895,0.0011760601,0.0008273437,0.000706414,0.0028396877],"category_scores_gemma":[0.0007888343,0.00018668053,0.0006814555,0.00056692975,0.00057789317,0.0013196573,0.00070798333,0.0028392475,0.00089304947],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00080240826,0.00040145905,0.0013960818,0.0041782255,0.00017251848,0.00074077985,0.00012036221,0.00088177493,0.0032717672,0.004715777,0.02326245,0.9600563],"study_design_scores_gemma":[0.0012934092,0.0029166641,0.008034882,0.009853736,0.00087902846,0.008517818,0.00043221685,0.002571654,0.0022282433,0.013687316,0.949489,0.000096044285],"about_ca_topic_score_codex":0.00037917864,"about_ca_topic_score_gemma":0.0018829824,"teacher_disagreement_score":0.0028396877,"about_ca_system_score_codex":0.00086786103,"about_ca_system_score_gemma":0.0005434054,"threshold_uncertainty_score":0.009499669},"labels":[],"label_agreement":null},{"id":"W4406697420","doi":"10.58931/cht.2025.4s0161","title":"Practical Considerations for Early Relapsed/Refractory Multiple Myeloma in the Canadian Landscape in 2024","year":2025,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; London Health Sciences Centre; Western University","funders":"","keywords":"Refractory (planetary science); Multiple myeloma; Medicine; Oncology; Intensive care medicine; Internal medicine; Biology; Astrobiology","score_opus":0.04380890724049456,"score_gpt":0.33824928806811133,"score_spread":0.29444038082761675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406697420","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0076899654,0.016404282,0.0013816899,0.9146286,0.0077721137,0.00013452682,0.0007413392,0.00018340703,0.05106411],"genre_scores_gemma":[0.21224387,0.054699708,0.021963105,0.58584064,0.019138243,0.00028411744,0.0018839996,0.0005337933,0.10341257],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99722373,0.0003917013,0.00022160522,0.00026962807,0.00094793574,0.0009453934],"domain_scores_gemma":[0.986459,0.0008404209,0.00041884635,0.00015918838,0.0052162376,0.0069061327],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038127494,0.0005634138,0.00050598034,0.0018176741,0.007840784,0.004700991,0.0030126753,0.0059731035,0.027427131],"category_scores_gemma":[0.010646814,0.00035639358,0.000807534,0.0014573405,0.0025717365,0.0019342444,0.0033430674,0.005676676,0.0026991295],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000115589675,0.00013545247,0.016230416,0.00042413108,0.000034425364,0.006125544,0.0011719674,0.0004669586,0.00083591987,0.015867556,0.8076938,0.15089831],"study_design_scores_gemma":[0.000057702495,0.000098354176,0.024592828,0.0015943432,0.00005881308,0.0064202333,0.004197215,0.0005616096,0.00023893581,0.009463177,0.9525773,0.00013945141],"about_ca_topic_score_codex":0.85902995,"about_ca_topic_score_gemma":0.9563412,"teacher_disagreement_score":0.14097005,"about_ca_system_score_codex":0.03441397,"about_ca_system_score_gemma":0.15471372,"threshold_uncertainty_score":0.28360045},"labels":[],"label_agreement":null},{"id":"W4408507497","doi":"10.58931/cht.2025.4s0262","title":"Momelotinib Usage Within Our Current Canadian Myelofibrosis Armamentarium","year":2025,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Myelofibrosis; Current (fluid); Medicine; Internal medicine; Engineering","score_opus":0.018587110024780217,"score_gpt":0.3005025020663963,"score_spread":0.2819153920416161,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408507497","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13160229,0.20515952,0.0042084525,0.111644566,0.003284734,0.0006692666,0.016626826,0.0012600196,0.5255442],"genre_scores_gemma":[0.69270456,0.12463073,0.010062866,0.060176697,0.002937525,0.00040626552,0.01817839,0.00038029085,0.090522714],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99952877,0.000054247423,0.00002616678,0.00007626249,0.00017505106,0.00013953718],"domain_scores_gemma":[0.99863535,0.000059015918,0.00012220805,0.000027007864,0.0004381949,0.0007181168],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005877569,0.00034246332,0.0003614558,0.00066271034,0.0017883554,0.0012550708,0.00076719915,0.0006272855,0.02047403],"category_scores_gemma":[0.0016334535,0.000106080835,0.00039392844,0.0014079731,0.00039391263,0.00048348188,0.0006531747,0.0013713529,0.002213218],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010095044,0.00023260446,0.026050465,0.0008342694,0.0001863176,0.0010715858,0.00032484235,0.0009974347,0.0056653433,0.009192915,0.3380294,0.61640525],"study_design_scores_gemma":[0.00024171539,0.00018988206,0.02813996,0.00054325495,0.00016217127,0.001720728,0.00014187724,0.00031400207,0.0009717332,0.00079950655,0.9667359,0.00003927196],"about_ca_topic_score_codex":0.51279604,"about_ca_topic_score_gemma":0.7536124,"teacher_disagreement_score":0.48720396,"about_ca_system_score_codex":0.015975224,"about_ca_system_score_gemma":0.022661543,"threshold_uncertainty_score":0.9801464},"labels":[],"label_agreement":null},{"id":"W4409987547","doi":"10.58931/cht.2025.4164","title":"Central Nervous System Relapse of Aggressive B-cell Lymphoma: Insights Into Current Treatment Approaches","year":2025,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Royal College of Pathologists of Australasia","keywords":"Lymphoma; Central nervous system; Medicine; Current (fluid); Aggressive lymphoma; Oncology; Neuroscience; Intensive care medicine; Internal medicine; Biology; Rituximab; Engineering","score_opus":0.02649810773108343,"score_gpt":0.2737271228354629,"score_spread":0.24722901510437947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409987547","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0022433437,0.9862307,0.0011042424,0.0076454505,0.00040209526,0.000025981395,0.000052073985,0.000037964706,0.0022581255],"genre_scores_gemma":[0.027350806,0.9617927,0.0036050924,0.0039430466,0.0022082888,0.00011874989,0.00024634454,0.000019816353,0.00071517006],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993229,0.0002131494,0.0001094725,0.00013185601,0.00013250406,0.00009015016],"domain_scores_gemma":[0.99823284,0.000919815,0.00019203234,0.000058399677,0.00042465588,0.00017217099],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023634331,0.00065735914,0.0013977315,0.0016129537,0.00039986972,0.0019583427,0.0015658642,0.0011606202,0.002473835],"category_scores_gemma":[0.0032996142,0.0002771285,0.0009988967,0.0007768391,0.00086114474,0.002202437,0.0009932346,0.0033290505,0.0007820901],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036370885,0.00029792145,0.0024654206,0.0050661205,0.00018223474,0.00040436635,0.00019622175,0.0012226017,0.0008409545,0.006697948,0.016620804,0.96564174],"study_design_scores_gemma":[0.0005552667,0.0026992399,0.011769489,0.03641187,0.0016285533,0.006385266,0.0017040768,0.006697083,0.00170592,0.039015915,0.891223,0.00020423828],"about_ca_topic_score_codex":0.0018076573,"about_ca_topic_score_gemma":0.0041964194,"teacher_disagreement_score":0.002473835,"about_ca_system_score_codex":0.0017077561,"about_ca_system_score_gemma":0.002364688,"threshold_uncertainty_score":0.012499154},"labels":[],"label_agreement":null},{"id":"W4409993061","doi":"10.58931/cht.2025.4167","title":"Diagnosis and Management of Small Lymphocytic Lymphoma (SLL)Versus Chronic Lymphocytic Leukemia","year":2025,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Alberta Health Services","funders":"","keywords":"Chronic lymphocytic leukemia; Medicine; Lymphoma; Leukemia; Oncology; Immunology","score_opus":0.02322234478264082,"score_gpt":0.2895352835417574,"score_spread":0.26631293875911655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409993061","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.23986836,0.5001953,0.014469047,0.12718199,0.005015683,0.00040365194,0.0003407704,0.00023553318,0.11228964],"genre_scores_gemma":[0.8759167,0.08909731,0.0072285277,0.017991098,0.0066197654,0.00015949184,0.00035395983,0.000050604074,0.0025825659],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99838996,0.0005427097,0.00018677529,0.00015094124,0.00046966184,0.0002600004],"domain_scores_gemma":[0.99869365,0.0003719106,0.00025336858,0.000030060313,0.00024646294,0.00040459586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021899503,0.00024236128,0.00073257176,0.0009672375,0.0010791899,0.0016539342,0.0006206453,0.00082134875,0.0012386852],"category_scores_gemma":[0.006393983,0.00013745618,0.00024658313,0.0006348142,0.0015579157,0.0008759646,0.0014132545,0.0016909658,0.0003197942],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012442187,0.0002184504,0.07252656,0.000809209,0.00008695781,0.0077374005,0.0013082585,0.0010678092,0.004847084,0.013194904,0.036249377,0.8607097],"study_design_scores_gemma":[0.001072422,0.0033766506,0.24251047,0.011894291,0.0003963714,0.099622086,0.012337342,0.0038329645,0.0045047086,0.029805189,0.59037364,0.00027388427],"about_ca_topic_score_codex":0.01152778,"about_ca_topic_score_gemma":0.025733892,"teacher_disagreement_score":0.01152778,"about_ca_system_score_codex":0.0034243083,"about_ca_system_score_gemma":0.0042263246,"threshold_uncertainty_score":0.024845183},"labels":[],"label_agreement":null},{"id":"W4409993746","doi":"10.58931/cht.2025.4166","title":"Hemophagocytic Lymphohistiocytosis and Other Cytokine Storm Syndromes in Adults","year":2025,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Autoimmune and Inflammatory Disorders Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; University of British Columbia","funders":"Dalhousie University","keywords":"Hemophagocytic lymphohistiocytosis; Cytokine storm; Medicine; Storm; Immunology; Geography; Meteorology; Internal medicine; Coronavirus disease 2019 (COVID-19); Disease","score_opus":0.012649287561128392,"score_gpt":0.2741008994893592,"score_spread":0.2614516119282308,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409993746","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88026994,0.06811068,0.005109697,0.0018365025,0.00029161136,0.0002567098,0.0013716458,0.00037712275,0.042376008],"genre_scores_gemma":[0.9830716,0.01074857,0.0011943766,0.00077974435,0.0002927384,0.000058399455,0.0009371346,0.000017998706,0.002899393],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998677,0.000018101573,0.00001821646,0.000030388099,0.000026910657,0.000038592538],"domain_scores_gemma":[0.9998294,0.000026682803,0.00005840367,0.0000082749075,0.000022346596,0.000054864915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013127104,0.0004622124,0.00038271106,0.00061960006,0.00036481643,0.00033825985,0.00016854264,0.0004933131,0.0021998608],"category_scores_gemma":[0.00061751076,0.00013669781,0.00023992876,0.00063422247,0.00024878263,0.00051570934,0.00040964654,0.0005087415,0.0005661724],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00093502,0.00013667681,0.4925305,0.0007402431,0.00012911379,0.3468424,0.0010552971,0.00040193892,0.019690504,0.0038291914,0.013935508,0.119773574],"study_design_scores_gemma":[0.00005970726,0.00027632987,0.18558252,0.00039783385,0.000077567944,0.7878272,0.00032200027,0.00031028187,0.0014895347,0.0020090153,0.02162148,0.000026626378],"about_ca_topic_score_codex":0.0007732224,"about_ca_topic_score_gemma":0.0006479884,"teacher_disagreement_score":0.0021998608,"about_ca_system_score_codex":0.00020976065,"about_ca_system_score_gemma":0.00025431468,"threshold_uncertainty_score":0.0073592663},"labels":[],"label_agreement":null},{"id":"W4409993751","doi":"10.58931/cht.2025.4163","title":"Richter Transformation in the Canadian Landscape: Clinical Perspectives and Emerging Trends","year":2025,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"CNS Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; Hôpital du Sacré-Cœur de Montréal","funders":"","keywords":"Transformation (genetics); Geography; Biology","score_opus":0.01575898755890943,"score_gpt":0.3218831674849407,"score_spread":0.3061241799260313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409993751","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004434549,0.9185218,0.00057471474,0.054385874,0.001254694,0.00002312935,0.00044872303,0.00006367196,0.020292798],"genre_scores_gemma":[0.03562075,0.95098305,0.0013316525,0.007813033,0.001427917,0.000016277485,0.00044985,0.000028322402,0.0023291907],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99894243,0.00010603123,0.000063891704,0.00011611296,0.0005383408,0.00023308203],"domain_scores_gemma":[0.99568033,0.0004136446,0.00031650643,0.000041132247,0.0027883095,0.00075994665],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001619874,0.00050583587,0.0006630086,0.002788572,0.002013012,0.003082379,0.0011523453,0.0009892927,0.0065071513],"category_scores_gemma":[0.004156451,0.0001625373,0.00039696405,0.005225256,0.0019597895,0.0014701847,0.001051718,0.002330504,0.0007998862],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021431662,0.000071425755,0.01698231,0.004460672,0.000092862,0.0017578964,0.0017406804,0.0005383225,0.0009828964,0.02050103,0.17628223,0.7763753],"study_design_scores_gemma":[0.000026069258,0.000071375944,0.014935892,0.003922756,0.00014302217,0.0032937163,0.0025011385,0.0002951349,0.00032666087,0.003999778,0.9704047,0.000079750556],"about_ca_topic_score_codex":0.7947922,"about_ca_topic_score_gemma":0.90190405,"teacher_disagreement_score":0.20520782,"about_ca_system_score_codex":0.026123432,"about_ca_system_score_gemma":0.06091411,"threshold_uncertainty_score":0.41283262},"labels":[],"label_agreement":null},{"id":"W4409994026","doi":"10.58931/cht.2025.4165","title":"Front-line Treatment of B-cell Acute Lymphoblastic Leukemia in Canada: Current Strategies and Evolving Paradigms","year":2025,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University","funders":"","keywords":"Front line; Current (fluid); Line (geometry); Front (military); Computer science; Political science; Geography; Engineering; Mathematics; Electrical engineering; Law; Meteorology","score_opus":0.012938679201887491,"score_gpt":0.26879415671149826,"score_spread":0.25585547750961074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409994026","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0082821045,0.92767483,0.0013031083,0.038324956,0.00081805076,0.00011724747,0.0011026389,0.00010325073,0.022273835],"genre_scores_gemma":[0.039685898,0.9463187,0.0036858136,0.0060640527,0.00038904577,0.00005859111,0.0011513142,0.00003593653,0.0026107396],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987664,0.00017619076,0.00010526262,0.00009468744,0.0006004044,0.0002570751],"domain_scores_gemma":[0.99773335,0.00020248453,0.00018741944,0.000029895906,0.0014166622,0.00043008148],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001714844,0.00047773198,0.0006859694,0.0016169316,0.0016486596,0.0021913813,0.001258173,0.0005647401,0.0042758225],"category_scores_gemma":[0.0029148932,0.00015982198,0.0005504361,0.0037672513,0.0010588862,0.0008790817,0.0010046656,0.0020893796,0.00057455286],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033345315,0.00010106977,0.0076866737,0.006827095,0.00014879904,0.0005138886,0.0008050289,0.0013930753,0.001206936,0.013033741,0.10243158,0.8655187],"study_design_scores_gemma":[0.00014724134,0.00014985658,0.025959788,0.009330257,0.00034902562,0.00091384654,0.0013356177,0.000584168,0.0009815907,0.0034569262,0.95671815,0.00007351981],"about_ca_topic_score_codex":0.8919747,"about_ca_topic_score_gemma":0.9443586,"teacher_disagreement_score":0.10802531,"about_ca_system_score_codex":0.041493114,"about_ca_system_score_gemma":0.09439704,"threshold_uncertainty_score":0.30105507},"labels":[],"label_agreement":null},{"id":"W4410304943","doi":"10.58931/cht.2025.4s0368","title":"Hypertension as a Cardiovascular Toxicity of Bruton’s Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukemia","year":2025,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Chronic lymphocytic leukemia; Medicine; Bruton's tyrosine kinase; Tyrosine kinase; Toxicity; Internal medicine; Leukemia; Cardiology; Receptor","score_opus":0.014782015728558128,"score_gpt":0.27032406567773637,"score_spread":0.25554204994917823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410304943","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016235632,0.99436027,0.00025405848,0.0009500637,0.00027626302,0.000013641174,0.00009426566,0.00001392599,0.0024140598],"genre_scores_gemma":[0.027296597,0.96701694,0.000488959,0.00217695,0.0006894273,0.000031742704,0.00020601241,0.000008087217,0.002085289],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9994209,0.00019611685,0.00011224407,0.000060465733,0.00016554716,0.000044711862],"domain_scores_gemma":[0.9993709,0.00036454567,0.00012648612,0.00001156348,0.00010259954,0.000023987412],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000697553,0.00026698955,0.0007184767,0.00055426854,0.000245034,0.00073921995,0.00030255457,0.00055861863,0.0029583278],"category_scores_gemma":[0.0010158365,0.0001319876,0.00095044426,0.0006632215,0.00023332286,0.0004956777,0.00031819334,0.0009404787,0.00044428275],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038671005,0.000077559904,0.0014774967,0.0304256,0.0005470548,0.001106137,0.00026302063,0.00058896776,0.00408652,0.003121586,0.044083685,0.91383564],"study_design_scores_gemma":[0.00020423942,0.00087171275,0.008750846,0.010782177,0.0012487817,0.0075982455,0.00016799042,0.00026413964,0.0026047048,0.002193246,0.96525496,0.00005887932],"about_ca_topic_score_codex":0.0012339654,"about_ca_topic_score_gemma":0.004442549,"teacher_disagreement_score":0.0029583278,"about_ca_system_score_codex":0.0004115867,"about_ca_system_score_gemma":0.0008045389,"threshold_uncertainty_score":0.009896576},"labels":[],"label_agreement":null},{"id":"W4411729473","doi":"10.58931/cht.2025.4s0469","title":"Advancing BTK Inhibition: Non‑Covalent Bruton Tyrosine Kinase Inhibitors and Their Emerging Role in Canadian Practice","year":2025,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Spinal Cord Injury BC; BC Cancer Agency","funders":"Hebrew University of Jerusalem","keywords":"Bruton's tyrosine kinase; Tyrosine kinase; Covalent bond; Chemistry; Biochemistry; Signal transduction","score_opus":0.005584451970101021,"score_gpt":0.2758105374282682,"score_spread":0.2702260854581672,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411729473","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009497758,0.7942796,0.0028823137,0.12783624,0.0037323055,0.000102782295,0.00047627432,0.00017292776,0.06101986],"genre_scores_gemma":[0.09791652,0.83786124,0.0064589474,0.031426676,0.0027441261,0.000067015775,0.0006072242,0.00009296875,0.022825243],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99884415,0.0002096105,0.00006988873,0.00014056005,0.0005379274,0.00019773774],"domain_scores_gemma":[0.9968347,0.00044555205,0.000342926,0.000077458724,0.0014288367,0.0008705169],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002792784,0.0004973882,0.00054534135,0.0013653642,0.0011819139,0.0025284835,0.0012376981,0.0017415365,0.012868895],"category_scores_gemma":[0.0037571837,0.00019144973,0.0003717728,0.001863864,0.002115503,0.001677907,0.0014037999,0.002985878,0.0017200485],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00059357344,0.00018461407,0.0021821025,0.0017467785,0.000071566225,0.000641827,0.0003908753,0.0006800143,0.0041413275,0.028123815,0.14115332,0.8200901],"study_design_scores_gemma":[0.0001946484,0.0002404488,0.0025770157,0.0010139215,0.00004879301,0.0007934179,0.00019254496,0.00032161677,0.0011503773,0.004725205,0.98870766,0.000034393877],"about_ca_topic_score_codex":0.23695503,"about_ca_topic_score_gemma":0.42808595,"teacher_disagreement_score":0.76304495,"about_ca_system_score_codex":0.015216492,"about_ca_system_score_gemma":0.02471162,"threshold_uncertainty_score":0.47115165},"labels":[],"label_agreement":null},{"id":"W4414057587","doi":"10.58931/cht.2025.4s0570","title":"Expert Discussion: Building Unique Networks and Partnerships to Bring Novel Therapies to Remote Patients","year":2025,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Thunder Bay Regional Health Sciences Centre; Ottawa Hospital","funders":"McMaster University; University of Ottawa","keywords":"MEDLINE; Raising (metalworking); Patient care; Patient privacy; Best practice; Key (lock)","score_opus":0.033866605633873156,"score_gpt":0.32028929606258716,"score_spread":0.286422690428714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414057587","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019973922,0.0022816344,0.00039888328,0.96887064,0.023226844,0.000037785267,0.000095333926,0.000041654228,0.0048473952],"genre_scores_gemma":[0.008386657,0.009419606,0.0017817012,0.93734837,0.0267739,0.00012831276,0.00020087224,0.000058128604,0.015902469],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98490024,0.0050978395,0.0009685609,0.0013630049,0.0051437845,0.0025266395],"domain_scores_gemma":[0.90993303,0.023058223,0.002455753,0.0015999629,0.041702695,0.021250378],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015870618,0.00087816414,0.0008293406,0.00081293494,0.0075047472,0.005245613,0.003199792,0.021762354,0.032559596],"category_scores_gemma":[0.07705226,0.00046164502,0.0015164035,0.00084989454,0.0043629953,0.0069938735,0.0049381605,0.020778192,0.0076946677],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008095423,0.000006327708,0.0001749041,0.000075205804,0.000004486863,0.00011313537,0.00016814076,0.000025676292,0.000042335152,0.0009616103,0.9910936,0.007326528],"study_design_scores_gemma":[0.000035943063,0.000014528503,0.0003276324,0.00081988797,0.000018316457,0.00057283166,0.0014575508,0.00010067194,0.00010157238,0.0032402019,0.99327314,0.000037706537],"about_ca_topic_score_codex":0.047121726,"about_ca_topic_score_gemma":0.09361909,"teacher_disagreement_score":0.047121726,"about_ca_system_score_codex":0.011262415,"about_ca_system_score_gemma":0.03755565,"threshold_uncertainty_score":0.10892272},"labels":[],"label_agreement":null},{"id":"W4414384075","doi":"10.58931/cht.2025.4272","title":"Front-line Treatment for Chronic Lymphocytic Leukemia in 2025: Finite Duration Versus Continuous Treatment","year":2025,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Chronic lymphocytic leukemia; Malignancy; Disease; Lymphoproliferative disease; Tyrosine kinase; Hematologic malignancy; Leukemia","score_opus":0.03534443402336911,"score_gpt":0.3317999994173451,"score_spread":0.296455565393976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414384075","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0026103768,0.9891571,0.00022449526,0.003055489,0.00038313525,0.000022268865,0.00012005862,0.0000066213665,0.004420538],"genre_scores_gemma":[0.04395239,0.9466775,0.0011675215,0.0045938347,0.0008727537,0.00006479958,0.00046531454,0.000011170803,0.0021947364],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993231,0.00018635976,0.000095636744,0.00007559272,0.00024328737,0.00007604282],"domain_scores_gemma":[0.99907684,0.00041808322,0.0001630129,0.00001873861,0.00022892113,0.000094416915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001913425,0.00021735742,0.0008476756,0.00057887106,0.00024956066,0.0012416253,0.00076712057,0.0005929543,0.004263262],"category_scores_gemma":[0.0022580437,0.00010265459,0.00071513775,0.00081554195,0.000337967,0.00080805126,0.00034074706,0.0011532635,0.0005739937],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013584913,0.00007590258,0.0016371482,0.009728788,0.00031933544,0.00010145754,0.00010178376,0.0002869006,0.00090979144,0.0044903425,0.01863394,0.9623561],"study_design_scores_gemma":[0.0013035807,0.0016183279,0.018654412,0.029377654,0.001896339,0.0015426156,0.0003654074,0.00044685596,0.0010582078,0.0039350744,0.9397202,0.000081346465],"about_ca_topic_score_codex":0.010974266,"about_ca_topic_score_gemma":0.048043616,"teacher_disagreement_score":0.010974266,"about_ca_system_score_codex":0.002981193,"about_ca_system_score_gemma":0.002469486,"threshold_uncertainty_score":0.021820784},"labels":[],"label_agreement":null},{"id":"W4414384080","doi":"10.58931/cht.2025.4273","title":"Intensive Versus Non-intensive Therapy for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)","year":2025,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Venetoclax; Myeloid leukemia; Regimen; Clinical trial; Azacitidine; Chemotherapy; Chemotherapy regimen; Drug; Leukemia","score_opus":0.013331096633161755,"score_gpt":0.2816588606524685,"score_spread":0.26832776401930675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414384080","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98276585,0.010313131,0.00072634633,0.0010336564,0.00043054787,0.00034422617,0.0011599654,0.000018399225,0.0032079364],"genre_scores_gemma":[0.99507564,0.0015723,0.0003874983,0.0010555425,0.0003490451,0.00025576973,0.00085008057,0.000003995644,0.00045014487],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99859554,0.00070116646,0.00017564076,0.0002508006,0.0001411184,0.0001357956],"domain_scores_gemma":[0.99823606,0.0007570622,0.00049388537,0.00014059202,0.000046747922,0.0003257047],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015929715,0.00018347063,0.0007474145,0.00026673335,0.00024238763,0.00060007436,0.0003132268,0.00060562586,0.00347353],"category_scores_gemma":[0.0029856453,0.00009863707,0.0013675458,0.0003556908,0.00037347022,0.0008972461,0.00051735755,0.0009842152,0.00031899245],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.43574676,0.0032953348,0.2997138,0.0016155752,0.0057832357,0.00026217886,0.00036658958,0.0014955977,0.00307395,0.0024181867,0.006287997,0.23994084],"study_design_scores_gemma":[0.035541393,0.14657773,0.7784754,0.0005753928,0.004437933,0.0007369651,0.00058963813,0.0032934358,0.0014519338,0.0041385316,0.024097187,0.000084404586],"about_ca_topic_score_codex":0.0003777877,"about_ca_topic_score_gemma":0.0012615054,"teacher_disagreement_score":0.00347353,"about_ca_system_score_codex":0.00041554528,"about_ca_system_score_gemma":0.00040130195,"threshold_uncertainty_score":0.011620104},"labels":[],"label_agreement":null},{"id":"W4414384084","doi":"10.58931/cht.2025.4271","title":"Cellular Therapy and Follicular Lymphoma: Where Do We Stand in 2025?","year":2025,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Follicular lymphoma; Follicular phase; Adverse effect; Lymphoma; Disease; International Prognostic Index","score_opus":0.01828241181672316,"score_gpt":0.28201133139322987,"score_spread":0.2637289195765067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414384084","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019095189,0.98441666,0.000041786618,0.012765128,0.0014863919,0.00000482147,0.000022198124,0.0000054607067,0.0010666195],"genre_scores_gemma":[0.003038062,0.98283845,0.00030594788,0.010219171,0.0023843804,0.000018308197,0.000057425957,0.0000070760775,0.0011311795],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988764,0.00035943036,0.0001823863,0.00010511028,0.0003461632,0.00013050994],"domain_scores_gemma":[0.9959972,0.001817993,0.0003705232,0.000063921434,0.0013490986,0.00040122378],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037031972,0.000529718,0.0016144064,0.0013424059,0.0007303335,0.0028089737,0.0010870384,0.002611547,0.0068859914],"category_scores_gemma":[0.0056132427,0.00024491933,0.000764008,0.0018923158,0.0012007813,0.0045583416,0.0010473606,0.0033134052,0.0020597696],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053362455,0.00006687106,0.00079545885,0.011759654,0.00017053974,0.00021229155,0.0002338829,0.00016370206,0.0007321241,0.0077427262,0.09684343,0.8807457],"study_design_scores_gemma":[0.00008855305,0.0002816729,0.0014534644,0.016165076,0.00028168256,0.0003726682,0.0006447505,0.00008788019,0.00011881744,0.0048394143,0.9756309,0.00003508591],"about_ca_topic_score_codex":0.011622723,"about_ca_topic_score_gemma":0.037132036,"teacher_disagreement_score":0.011622723,"about_ca_system_score_codex":0.0026053155,"about_ca_system_score_gemma":0.0073485007,"threshold_uncertainty_score":0.023110151},"labels":[],"label_agreement":null},{"id":"W4414384116","doi":"10.58931/cht.2025.4275","title":"Concise Review of Chronic Myelomonocytic Leukemia in Canada in 2025","year":2025,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Chronic myelomonocytic leukemia; Myeloid leukemia; Incidence (geometry); Myeloproliferative neoplasm; Myelodysplastic syndromes; Leukemia","score_opus":0.012749193287566392,"score_gpt":0.28878351381781786,"score_spread":0.27603432053025145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414384116","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021782613,0.96929604,0.00010007859,0.010302079,0.013487971,0.000025483861,0.000479,0.000021419242,0.006070062],"genre_scores_gemma":[0.0016001202,0.9804273,0.00021410106,0.004913622,0.007963557,0.000015036857,0.0006393859,0.000011107486,0.0042157415],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99922335,0.00007849143,0.00011785432,0.000064792155,0.00042165225,0.00009383092],"domain_scores_gemma":[0.99494344,0.00032916633,0.00029912285,0.000042916952,0.0036289557,0.00075636123],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011059205,0.00082528393,0.0011874456,0.0072125494,0.0010600535,0.0021350991,0.0011972266,0.0015460014,0.01058622],"category_scores_gemma":[0.004279458,0.0003260305,0.0005331191,0.008362486,0.0008034272,0.001477751,0.0009631705,0.0019487026,0.0030976036],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004679484,0.000016446536,0.00071356643,0.0066226725,0.0000451739,0.0005045185,0.00010813479,0.00014146636,0.00020726123,0.0018524372,0.7517624,0.23797916],"study_design_scores_gemma":[0.0000055683963,0.000010150165,0.0012813535,0.0040623043,0.000036962734,0.00078775815,0.00008008078,0.000020969223,0.000030382918,0.00016078757,0.9935081,0.000015541833],"about_ca_topic_score_codex":0.38496733,"about_ca_topic_score_gemma":0.6153303,"teacher_disagreement_score":0.38496733,"about_ca_system_score_codex":0.011578313,"about_ca_system_score_gemma":0.03127888,"threshold_uncertainty_score":0.7654531},"labels":[],"label_agreement":null},{"id":"W4415701428","doi":"10.58931/cht.2025.4s0676","title":"Double-Exposed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Clinical Approach and Management","year":2025,"lang":"","type":"article","venue":"Canadian Hematology Today","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Bruton's tyrosine kinase; Chronic lymphocytic leukemia; Lymphocytic infiltration; Ibrutinib; Immunotherapy; Clinical trial; Tyrosine kinase; Lymphoma; Refractory (planetary science)","score_opus":0.038119414519371064,"score_gpt":0.31643528583161257,"score_spread":0.2783158713122415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415701428","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.023699218,0.8241203,0.014957525,0.07061659,0.0019866533,0.00039630453,0.00032910903,0.0003211965,0.06357313],"genre_scores_gemma":[0.16966522,0.76781726,0.025492568,0.02072038,0.004118539,0.00021253107,0.0006761345,0.00007640698,0.011220993],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997069,0.00004934147,0.000031065545,0.000028293596,0.00013155544,0.00005269933],"domain_scores_gemma":[0.99955887,0.00003946421,0.00006192507,0.000008692117,0.00018574538,0.00014519988],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005842853,0.00035827898,0.00048089528,0.00073876535,0.0009361214,0.0014017478,0.0007705531,0.0007518489,0.0013687523],"category_scores_gemma":[0.0011534567,0.00010291432,0.0002076351,0.0008132507,0.0007282645,0.0007851252,0.0009885818,0.0017924819,0.00043397286],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011387822,0.0000864041,0.01269779,0.0020300408,0.000058691756,0.008870305,0.001138154,0.0008008663,0.0054615247,0.00662127,0.09947122,0.86264974],"study_design_scores_gemma":[0.00010228681,0.0002684602,0.023221955,0.004498781,0.00013707475,0.047768645,0.0032577396,0.0006025925,0.0014432803,0.0076521956,0.9109543,0.00009272376],"about_ca_topic_score_codex":0.054199122,"about_ca_topic_score_gemma":0.14710861,"teacher_disagreement_score":0.054199122,"about_ca_system_score_codex":0.0034815625,"about_ca_system_score_gemma":0.009715772,"threshold_uncertainty_score":0.107767284},"labels":[],"label_agreement":null},{"id":"W4417129956","doi":"10.58931/cht.2025.4378","title":"Practical Management of Aggressive B-Cell Lymphomas with CD20×CD3 Bispecific Antibodies","year":2025,"lang":"","type":"article","venue":"Canadian Hematology Today","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval; Centre hospitalier de l'Université Laval","funders":"Centre Hospitalier Universitaire de Québec; Royal College of Physicians and Surgeons of Canada; Université Laval","keywords":"Chimeric antigen receptor; Lymphoma; Cytokine release syndrome; Bispecific antibody; Blinatumomab; Immunotherapy; Aggressive lymphoma; Antibody","score_opus":0.023746943467071464,"score_gpt":0.3227101856237286,"score_spread":0.29896324215665715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417129956","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.038621657,0.66663903,0.066167526,0.103792965,0.00348578,0.0006987299,0.00040280184,0.0015108587,0.11868067],"genre_scores_gemma":[0.27506042,0.5487254,0.09837367,0.04293943,0.0070909974,0.00055810553,0.0010100744,0.00024200877,0.025999848],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99964833,0.00006740518,0.000035548564,0.000025116859,0.00014686199,0.00007683713],"domain_scores_gemma":[0.9996805,0.000055692828,0.00004761062,0.000012082441,0.000105935454,0.00009815899],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006274491,0.0005405461,0.0006541811,0.0008480456,0.0010272807,0.001032234,0.0007992313,0.0011350639,0.0024525623],"category_scores_gemma":[0.0011858682,0.00019048505,0.0003828459,0.00060494227,0.0006466706,0.00073057157,0.00085372064,0.0025380503,0.0010079953],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001935454,0.00013482658,0.0050118384,0.0015403886,0.00005810179,0.028016716,0.00054994534,0.0013721526,0.009086231,0.0061555463,0.14404482,0.803836],"study_design_scores_gemma":[0.00016163784,0.00030324893,0.009619334,0.0016608367,0.0001337433,0.07048607,0.0010508244,0.0012793466,0.0053795897,0.009809367,0.90005016,0.0000657612],"about_ca_topic_score_codex":0.022807518,"about_ca_topic_score_gemma":0.057085343,"teacher_disagreement_score":0.022807518,"about_ca_system_score_codex":0.0022257536,"about_ca_system_score_gemma":0.003716894,"threshold_uncertainty_score":0.04534948},"labels":[],"label_agreement":null},{"id":"W4417129959","doi":"10.58931/cht.2025.4377","title":"New Developments in the Front‑line Treatment of Advanced Stage Classic Hodgkin Lymphoma: A Canadian Perspective","year":2025,"lang":"","type":"article","venue":"Canadian Hematology Today","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Perspective (graphical); Stage (stratigraphy); Clinical trial; Hodgkin lymphoma; MEDLINE; Paradigm shift","score_opus":0.015418309164467054,"score_gpt":0.2833311281488873,"score_spread":0.2679128189844202,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417129959","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0027027845,0.80150974,0.0016562814,0.15114388,0.005955169,0.00005040755,0.0004667152,0.000111196896,0.036403775],"genre_scores_gemma":[0.031027375,0.92883736,0.003953884,0.023770155,0.0048372257,0.000029719346,0.00045159704,0.00006038683,0.0070323218],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986959,0.00017115015,0.00009227428,0.00010654445,0.000688455,0.00024567664],"domain_scores_gemma":[0.99392575,0.0004899048,0.00027698447,0.00006191609,0.004145073,0.0011003133],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028857053,0.00054168334,0.0006359821,0.002080831,0.0016836606,0.0023192544,0.0011710186,0.0013306672,0.01003468],"category_scores_gemma":[0.0042448672,0.0001820933,0.000525382,0.0026573567,0.0016041495,0.001575074,0.0011116316,0.003946196,0.0013904837],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037649472,0.00011404095,0.0036627236,0.004105666,0.00010821261,0.0008981734,0.00069370854,0.00082277774,0.0023828468,0.024851203,0.30803874,0.65394545],"study_design_scores_gemma":[0.000059333277,0.0000861492,0.0034132565,0.0022385237,0.00010883199,0.0006156935,0.00036355417,0.00020314817,0.00033851506,0.0021751437,0.99035805,0.00003978774],"about_ca_topic_score_codex":0.62863165,"about_ca_topic_score_gemma":0.8066137,"teacher_disagreement_score":0.37136835,"about_ca_system_score_codex":0.01819736,"about_ca_system_score_gemma":0.04132979,"threshold_uncertainty_score":0.74711084},"labels":[],"label_agreement":null},{"id":"W4417129987","doi":"10.58931/cht.2025.4379","title":"Unique Toxicities of Novel Myeloma Therapies: Focus on Belantamab Mafodotin, Talquetamab, and Selinexor","year":2025,"lang":"","type":"article","venue":"Canadian Hematology Today","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surrey Place Centre","funders":"","keywords":"Multiple myeloma; Toxicity; Chimeric antigen receptor; Drug; Disease; Monoclonal antibody; Adverse effect; Bortezomib","score_opus":0.020146227947620308,"score_gpt":0.2911424927427976,"score_spread":0.27099626479517724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417129987","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11571821,0.8238588,0.005140594,0.026640384,0.0010530547,0.00006556364,0.00015010801,0.00017363914,0.027199568],"genre_scores_gemma":[0.5034838,0.46349,0.0069312183,0.01057784,0.004446038,0.00007740529,0.00034432235,0.000082632476,0.010566608],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99974436,0.00008449085,0.000021069678,0.000029785555,0.00007875818,0.00004144431],"domain_scores_gemma":[0.99966526,0.00011390194,0.00006652274,0.000014837822,0.00007737162,0.0000621922],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011301074,0.0002847402,0.00061409024,0.00040560396,0.00029392212,0.0007374335,0.000257004,0.00028771054,0.0012972319],"category_scores_gemma":[0.0005726784,0.00010203496,0.00042275887,0.0003510035,0.00038234473,0.0006808923,0.00048768971,0.0011834167,0.000231365],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008592179,0.00018392905,0.003777164,0.0013070708,0.00017750404,0.0017214711,0.00018633797,0.0013278542,0.024130788,0.008040348,0.018580075,0.93970823],"study_design_scores_gemma":[0.00073743047,0.0049368194,0.034002095,0.0011831232,0.0005189372,0.02764147,0.00030974776,0.0032432927,0.027356008,0.011173439,0.88881874,0.00007898232],"about_ca_topic_score_codex":0.00068080705,"about_ca_topic_score_gemma":0.004094944,"teacher_disagreement_score":0.0012972319,"about_ca_system_score_codex":0.0011412808,"about_ca_system_score_gemma":0.00063721766,"threshold_uncertainty_score":0.008280575},"labels":[],"label_agreement":null},{"id":"W4417130011","doi":"10.58931/cht.2025.4380","title":"Rational Use of Immunoglobulin in Adult Patients with Secondary Hypogammaglobulinemia in the Setting of Hematologic Malignancy: A Canadian Perspective","year":2025,"lang":"","type":"article","venue":"Canadian Hematology Today","topic":"Immunodeficiency and Autoimmune Disorders","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Blood Services; University of Calgary; Saskatchewan Health; Saskatchewan Health Authority","funders":"","keywords":"Hypogammaglobulinemia; Chronic lymphocytic leukemia; Antibody; Context (archaeology); Rituximab; Multiple myeloma; Lymphoma; Immunoglobulin G; Acute lymphocytic leukemia","score_opus":0.005257888975597179,"score_gpt":0.20592982171335247,"score_spread":0.2006719327377553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417130011","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03729185,0.44337556,0.0052088154,0.43555334,0.0047228322,0.0002470674,0.00074317766,0.00025434265,0.07260307],"genre_scores_gemma":[0.35564122,0.4913704,0.017415868,0.10954538,0.009568574,0.00018275408,0.0011339358,0.0001510051,0.014990802],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992791,0.0001532503,0.000103096696,0.00008152074,0.00024003893,0.00014310131],"domain_scores_gemma":[0.99641573,0.00025226522,0.00022931078,0.000035654964,0.0019016198,0.0011653417],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012902515,0.00036937668,0.0006344331,0.0013038148,0.0012827263,0.001545534,0.0013269678,0.0017280763,0.0041595153],"category_scores_gemma":[0.0040069637,0.00017382602,0.0005145003,0.0010252236,0.0007646373,0.0009820267,0.0009224824,0.0031055845,0.0007628833],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006633854,0.000525522,0.07804865,0.001694489,0.00016724133,0.011173015,0.0011749562,0.00096139195,0.0023609395,0.012369601,0.27648312,0.6143777],"study_design_scores_gemma":[0.00045278095,0.00066890335,0.14032304,0.0108548105,0.00045317924,0.019972552,0.003656535,0.0018618822,0.0008262966,0.0073968084,0.8133283,0.00020488333],"about_ca_topic_score_codex":0.30552918,"about_ca_topic_score_gemma":0.42202985,"teacher_disagreement_score":0.6944708,"about_ca_system_score_codex":0.009853782,"about_ca_system_score_gemma":0.022889009,"threshold_uncertainty_score":0.6075016},"labels":[],"label_agreement":null}]}